aws Hochtechnologie aws Life Science Life Science Portfolio Portfolio
2012/13 2013
Austrian Life Science Companies
As the Austrian government promotional bank, austria wirtschaftsservice is fulfilling the task of supporting Austria’s economy by funding companies and know-how transfer. The state-owned bank is particularly funding small and medium sized companies through guarantees, favorable credits, equity and other financial support. The aim of aws is to promote the setting-up of new companies, the growth of existing ones, regional development and the implementation of innovation and technologies. Our mandate ist to offer a broad range of company-related investments assistance programs, services and financing – from the pre-set up to the expansion and internationalization stages.
Over the past decade, Austria has established itself as a well-respected hub of the life science industry. The growing life science sector is reflected in the increasing interest shown by international businesses in doing deals in Austria. The country is also proving to be an attractive location for operations and significant inward investment for a number of multinational companies. These investments come on top of a whole series of international venture capital investments in Austrian life science.
a
Mag. Edeltraud Stiftinger Managing Director Austria Wirtschaftsservice Gesellschaft mbH
What makes Austria an interesting place for the life sciences are the close links between solid academic research and outstanding medical practice, access to highly-skilled and dedicated scientists and managers, paired with an active start-up community, and last, but certainly not least, an extremely effective government support system for innovative companies.
Furthermore the wide array of funding schemes available to life science start-ups contributes to this thriving environment. austria wirtschaftsservice, the Austrian national promotional bank, provides financial support for startup ideas for life-sciences through its funding programmes ‘aws PreSeed’ and ‘aws Seedfinancing’. Furthermore, austria wirtschaftsservice implements three initiative to close the financing gap for young, innovative companies. aws Business Angel fund provides co-financing for equity investments. It is aimed in particular at start-ups. aws ‘gründerfonds’ provides risk capital to companies with high growth
potential in the early stage as well as in the growth phase. These instruments are complemented by the Venture Capital initiative that undertakes co-investments with institutional investors. All these measures are now bearing fruit, creating new and exciting jobs while securing Austria’s future as a hot spot for innovation. We hope to have captured your attention for the aws Life Science Portfolio. It intends to provide you with more inside into the portfolio of aws funded Austrian life science companies, laying the ground for more investments into this burgeoning industry!
aws LISA – Life Science Austria The most innovative ideas in life sciences only make a difference once they have survived the journey from the laboratory bench to commercial launch. With aws LISA – Life Science Austria (LISA), austria wirtschaftsservice (aws), the Austrian government promotional bank,
created a one-stop-shop support programme serving the whole value chain of a life science start-up. Comprised of four pillars – Foster, Finance, Fuel and Advance – LISA provides tailor-made support measures for every stage of development.
Foster Entrepreneurial Spirit
Finance New Ventures
Fuel for Success
Advance Austrian Life Sciences
As a way of fostering an entrepreneurial culture, we run the business plan competition aws BoB – Best of Biotech, every two years. The goal of the competition is to motivate scientists and other creative individuals in the life sciences to translate their innovations into professional business plans by providing comprehensive and individualised coaching. Additionally they can win attractive cash prizes for the best business plan and the best business idea. Professional advice can mitigate the high risks encountered when a life science start-up is set up. That’s why on top of aws BoB – Best of Biotech, aws offers professional consulting and due diligence in the pre-start-up phase.
Focusing on start-up ideas in biotechnology and medical devices, aws provides financial support through two custom-designed funding programmes: aws PreSeed and aws Seedfinancing. aws PreSeed provides funding for the critical phase before a life science company is actually set up. Costs relating to the implementation of the science and the development of a business plan for a project can be funded with non-refundable awards of up to 200,000 Euro. aws Seedfinancing supports the start-up phase by providing up to 1 million Euro, combined with business advice. This Seedfinancing is then refunded when the company is making a profit or is sold.
LISA International Marketing promotes the Austrian life science sector on the international stage and is the first point of call for enquiries relating to it. Marketing Austria as a life sciences location and making its scientific and business success stories more widely known gives the Austrian life sciences a higher profile, and contributes to Austria’s positioning in international markets. We achieve our goal by maintaining a regular and high profile presence at the leading international life science conferences and exhibitions (Medtech, Biotech and Pharma) and public relations. Furthermore, companies will be supported in obtaining follow-up financing as well as offering sector specific lectures. Life science entrepreneurs can take advantage of insights provided by renowned specialists.
Austria as an attractive location for a life science business is in constant global competition for the best ideas as well as the best innovation support system. aws produces statistics, analyses and studies about the sector as a basis for key decision makers to offer them impetus for measures ensuring the competitiveness of the Austrian life science sector.
Biotech/Pharma AFFiRiS Akron Molecules angothera Annikki APEIRON Biologics APEPTICO Avienne Pharmaceuticals BDS Pharma Diagnosia Dutalys Eucodis Bioscience GmbH EveliQure Biotechnologies Evercyte F-star GAT Microencapsulation Haplogen Innovacell Biotechnologie INOXIA Lifesciences Inte:Ligand Lexogen Marinomed Mucokinetica OrigImm Panoptes Pharma PDC Biotech Procomcure Biotech ProFem RECARDIO roombiotic Savira SeaLife Pharma S-TARget therapeutics TAmiRNA Themis Bioscience The Siesta Group Tissue Med Biosciences TUBE Pharmaceuticals
— — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — —
18 20 22 24 26 28
90 92 94 96 98 100 102 104
— — — — — — — —
ugichem Valericon Valneva Vela Laboratories ViraTherpeutics Xiber Science XworX Zytoprotec
*
30 32 34 36 38 40 42 44 46 48 50 52 54 56 58 60 62 64 66 68 70 72 74 76 78 80 82 84 86 88
Medtech 108 110 112 114 116 118 120 122 124 126 128 130 132 134 136 138
*
140 142 144 146 148 150
— — — — — — — — — — — — — — — — — — — — — — —
4a medicom AFreeze Anagnostics CV Tec Dioptex DirectSens EMCOOLS Medical Cooling Systems EMTensor Ergospect impress iSYS Medizintechnik Jeder Lacerta Technologies medizinkraft solutions Murmur Detect mySugr Ovula ScarletRed SIMCharacters TissueGnostics Tyromotion VASCOPS VASEMA
* Detailed information upon request.
angothera
APEIRON Biologics
Dutalys
EveliQure Biotechnologies
F-star
Haplogen
Marinomed
10 UD
Akron Molecules
PC+PM
Mucokinetica
UD Under development
AFFiRiS
PC Preclinical Phase
I+II
BDS Pharma
I Clinical Phase I
PC+II +III
APEPTICO
INOXIA Lifesciences
II Clinical Phase II
PC
PC
Avienne Pharmaceuticals PC
II
III Clinical Phase III
Innovacell Biotechnologie
PC
UD
PM PreMarket
Annikki
Eucodis Bioscience
III
PC+M
M Marketed
Diagnosia
Evercyte
GAT Microencapsulation
PC
X Active
Supply & Services
Industrial Biotechnlogy
Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
Pregnancy, childbirth and the puerperium
D. of the genitourinary system
D. of the musculoskeletal system and connective tissue
D. of the skin and subcutaneous tissue
D. of the digestive system
D. of the respiratory system
D. of the circulatory system
D. of the eye and adnexa
D. of the nervous system
Mental and behavioural disorders
Endocrine, nutritional and metabolic diseases
Diseases (D.) of the blood and blood-forming organs and certain disorders involving the immune mechanism
Neoplasms
Certain infectious and parasitic diseases
Biotech Pharma
I PC+II
PM X
II
II UD
II X
UD X
PC X
PC X X
II
UD
Inte:Ligand X
Lexogen X
PC
UD
11
Panoptes Pharma
Procomcure Biotech
ProFem
12 Savira PC
SeaLife Pharma PC
S-TARget therapeutics
Themis Bioscience
TUBE Pharmaceuticals
Valneva
ViraTherapeutics TAmiRNA
Tissue Med Biosciences
PC UD
Valericon
UD Under development PC
PC Preclinical Phase
PC
RECARDIO
UD
I Clinical Phase I
PC
Xiber Science
II Clinical Phase II
OrigImm
PC
PC
UD
PC
ugichem
Zytoprotec
III Clinical Phase III
PC
PDC Biotech
I I I
PM PreMarket
PC
M Marketed
roombiotic
The Siesta Group
Vela Laboratories
XworX
X Active
Supply & Services
Industrial Biotechnlogy
Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
Pregnancy, childbirth and the puerperium
PC
D. of the genitourinary system
D. of the musculoskeletal system and connective tissue
D. of the skin and subcutaneous tissue
D. of the digestive system
D. of the respiratory system
D. of the circulatory system
D. of the eye and adnexa
D. of the nervous system
Mental and behavioural disorders
Endocrine, nutritional and metabolic diseases
Diseases (D.) of the blood and blood-forming organs and certain disorders involving the immune mechanism
Neoplasms
Certain infectious and parasitic diseases
Biotech Pharma
PC
PC+I
PC+II X
PM
PC UD
I X
UD
PC PC
PC+I+II +III+M PC
X
PC PC X
PC+II
13
4a medicom
IIb / PC
AFreeze
IIb / PC
III / A
III / A
Anagnostics
O / A
CVTec
IIb / UD
Dioptex
IIa+IIb / A
IIa+IIb / A
DirectSens
IIa+IIb / A
IIa+III / UD
IIa+III/UD
EMCOOLS Medical Cooling Systems
I+IIa/A
EMTensor
IIa / UD
Ergospect
I / A
impress
Lacerta Technologies
I / A
I / A
IIb / UD
iSYS Medizintechnik Jeder
Software for medical, veterinary medical and e-health applications
Biological-derived devices
Complementary therapy devices
Diagnostic and therapeutic radiation devices
Assistive products for persons with disability
Single use devices
Reusable devices
Ophtalmic and optical device
Non-active implantable devices
In vitro diagnostic devices
Hospital hardware
Electro mechanical medical devices
Dental devices
Medtech
I / A IIa / A
I / A
I / A
IIa / A
IIa / A
I / A
IIa / PC
IIa / PC
medizinkraft solutions
I / UD
I / UD
Murmur Detect
IIa / UD
mySugr
I
Ovula
IIa / UD
IIa / UD
ScarletRed
IIa / UD
SimCharacters
O / UD
TissueGnostics
I / A
Tyromotion
IIa / A
O / UD I / A
IIa / A
IIa / A
IIa / A IIb / UD+PC+A
VASCOPS VASEMA
14
I+IIa / A+UD UD Under development
I+IIa / A+UD PC Preclinical Phase
I Medical Device Class I
IIa Medical Device Class IIa
IIb Medical Device Class IIb
III Medical Device Class III
A Approved
O Other
15
Biotech / Pharma In Austria, the life sciences — including biotechnology and pharma — are viewed as being among the most important key technologies for driving forward new developments, and for developing economic potential. Over the last few decades a lively scene of innovative biotechnology / pharma companies has put Austria on the European life science map. 16
17
AFFiRiS
Products
is an innovative biotechnology company based in Vienna. Using its proprietary AFFITOME® technology, it is able to develop customized peptide-based vaccines called AFFITOPES®, targeting chronic diseases with attractive market values and unmet medical needs. Indications include Alzheimer’s disease, Parkinson’s disease, atherosclerosis, diabetes, and several others.
Technology
Market
—— Indications: Alzheimer’s disease, Parkinson’s disease, atherosclerosis, diabetes, dyslipidemia, and several others —— AFFITOME® is a fast and robust technology that delivers a pool of synthetic peptide vaccines (AFFITOPE®) for the treatment of chronic diseases. Autoimmune disease problems are avoided. —— AFFITOPES® mimic disease-associated structures like certain structures of ß-amyloid in Alzheimer’s disease. AFFITOPE® vaccination in Alzheimer’s induces an antibody immune response to target pathologic derivatives of ß-amyloid.
—— The global Alzheimer’s disease market is forecast to increase from $ 5.3bn in 2011 to $ 14.3bn in 2020. —— The Parkinson’s disease market was $ 4.6bn in 2012. —— The diabetes market in US alone was $ 20bn in 2010 and is expected to reach $ 35bn in 2020. —— The cardiovascular and dyslipidemia market was $ 100bn in 2009 and is expected to increase to $ 130bn in 2020.
18
Products
Indication
Stage of development
—— AD02
Alzheimer’s
Phase II
—— AD03
Alzheimer’s
Phase I
—— PD01A
Parkinson’s
Phase I
—— ATH01
Atherosclerosis
Phase I
Company Profile Founded: 2003 Legal Form: AG Employees: 101
AFFiRiS product
Management Team CEO: Walter Schmidt CSO: Frank Mattner CTO: Arne von Bonin CFO: Richard Westmoreland Public Funding aws: € 4.25M Others: € 6.623M Private Funding
AFFiRiS AG Karl-Farkas-Gasse 22 1030 Vienna, Austria +43 1 798 157 530 0 office@affiris.com www.affiris.com
€ 38.531M
Biotech / Pharma – 19
Akron Molecules
Products
is a growing clinical-stage biopharmaceutical company founded in 2010. Akron strives to improve treatment options for conditions of high unmet medical need, with a current focus on chronic pain. The lead drug candidate, AKR 202, is on track to enter a clinical phase II study in pain associated with osteoarthritis (OA) in Q4’13, having obtained a regulatory “thumbs up” from a BfArM scientific advice meeting. Top-line data from the clinical study with AKR 202 in OA pain is expected in Q1‘15.
Technology
Market
—— Akron Molecules has developed a “drug repurposing” strategy, i.e. systematic identification of new uses for existing compounds. —— AKR 202 is a once-daily oral compound with a favorable safety profile, also when administered over the long term. Efficacy has been shown across a range of industry-standard rodent models of pain, demonstrating reduction of pain and inflammation plus potentially disease-modifying effects. AKR 202 represents a novel mechanism of action for the treatment of pain (purinergic receptor modulation and enzyme inhibition), with a potential for first-in-class status.
—— Pain affects approximately 1 billion people worldwide with an estimated annual market value of close to $30bn. There is a large unmet need both due to lacking efficacy and particularly safety concerns of current pain treatments (analgesics). —— The initial focus indication of Akron is chronic pain associated with OA (a type of nociceptive/ inflammatory pain— $4.4bn market size in 2010), followed by chronic lower back pain, as well as other important chronic pain indications, including postherpetic neuralgia.
20
Products
Indication
Stage of development
—— AKR 202
Pain (initially pain associated with OA)
Phase II
—— AKR 203
Pain
Phase II
—— AKR 210
Pain
Preclinical
—— AKR 101
Obesity/metabolic disease
Preclinical
Company Profile Founded: 2010 Legal Form: GmbH Employees: 7
New pain treatments by Akron
Management Team CEO: Henrik Nilsson CSO: Shane McManus CAO: Lionel Wightman Managing Director: Manfred Reichl Public Funding aws Seed: Not disclosed FFG (Basis): Not disclosed Private Funding
Akron Molecules GmbH Helmut-Qualtinger-Gasse 2 1030 Vienna, Austria +43 1 23 604 29 info@akron-molecules.com www.akron-molecules.com
High single-digit million €
Biotech / Pharma – 21
angothera
Products
is developing treatments for mucosal immunoglobulin deficiency and its consequential diseases such as microbial infections. The first products are based on secretory antibodies from recombinant cell culture, plasma, or milk that are stable in the mucosa and can thus be given orally to patients.
Technology
Market
—— angothera’s oral antibody technology can be used to produce either nutraceuticals from natural milk or glycoengineered recombinant secretory antibodies. —— angothera is focusing on the development of products for mucosal immunoglobulin deficiency and its consequential disease. —— angothera is testing one of its preparations for the prevention of Clostridium difficile–associated disease. —— angothera has filed IP on specifically glycosylated secretory immunoglobulins and their use.
—— Mucosal immunoglobulin deficiency has a prevalence of more than 0.3 % in the western population; in Europe and the US approx. 3 million people are affected. Mucosal immunoglobulin deficiency is largely undetected. Only the consequences of the disease such as recurring infections, allergies, and autoimmune diseases are treated with varying success. —— The annual costs of Clostridium difficile infections for the health system in Europe are estimated to be more than 3 billion €. The additional costs per patient of C. diff. infection are estimated to be $ 2,000 to $ 90,000, depending on the severity of disease. —— angothera’s first product will be a nutraceutical that contributes to the maintenance of the normal function of the immune system and normal mucous membranes.
22
Products
Indication
Stage of development
—— Secretory Immunoglobulin
Immunodeficiency with predominantly antibody defects
preclinical
—— Recombinant Secretory Component-Lewis
Immunodeficiency with predominantly antibody defects
preclinical
—— Secretory Immunoglobulin
Enterocolitis due to Clostridium difficile
preclinical
—— Sigavit
Healthy mucosa
pre-market
Angothera technology
Company Profile Founded: 2012 Legal Form: GmbH Employees: 1 Management Team CEO: Gottfried Himmler
angothera GmbH
Public Funding
Donau-Oder Kanal IV SW 80 2301 Gross-Enzersdorf, Lower Austria, Austria +43 680 3323300 office@angothera.com www.angothera.com
aws PreSeed: € 200,000 Private Funding € 250,000
Biotech / Pharma – 23
Annikki
Products
develops industrial technologies for the processing of chemical-grade cellulose, xylan for novel green polymers, xylitol, arabinose derivatives, lignin derivatives for high-performance polymers, green resins, and low-cost carbon fibers for high-volume applications. Annikki´s highly integrated process technologies enable superior yields of products and the production of numerous downstream products without the isolation of intermediate chemicals, thereby leading to unmatched economics.
Technology
Market
—— Moderate temperature conserving lignin in natural state and avoiding byproducts such as furfural. —— Highly selective primary process yielding high purity product streams. —— Direct conversion of products from primary process to downstream products obviating costly isolation of intermediates. —— Proprietary and very efficient technology to separate C5 components xylose and arabinose and use them for individual processing. —— Technologies to make high quality lignin with excellent properties for further processing to high-performance polymers, green resins, and carbon fibers.
—— Addressing combined markets with current value of more than € 300 billion —— High-growth markets —— Solution to CO2 issue —— Green Chemicals —— Green Polymers —— Green Materials —— Green Carbon Fibers for high-volume markets —— Food —— Pharmaceuticals —— Cosmetics
24
—— Chemical-grade cellulose for many applications like thickening agents, binders, adhesives, dispersing agents, film formers, water-retention agents, suspension aids, surfactants, lubricants, emulsifiers, stabilizers, excipients, cellulose for rayon (viscose), etc.
—— Xylitol as non-carcinogenic, low-calorie sugar replacement product —— C5 chemical intermediates for diverse applications —— Green plastics at low cost —— High-toughness polymers from lignin —— Carbon fibers from lignin
Company Profile Founded: 2007 Legal Form: GmbH Employees: 15
Annikki laboratory
Management Team CEO: Ortwin Ertl CTO: Chris Prince Public Funding aws Seed: € 550,000 FFG: € 4M Private Funding
Annikki GmbH Rankengasse 28 8020 Graz, Styria, Austria +43 316 765 114 10 ortwin.ertl@annikki.at www.annikki.at
€ 3M
Biotech / Pharma – 25
APEIRON Biologics focuses on biological and immunological treatments of cancer. Its portfolio consists of 5 clinical projects and some preclinical approaches. Its lead project, mAb ch14.18 / CHO (APN311) is in phase III against neuroblastoma, nearing full recruitment. The immunocytokine hu14.18-IL2 (APN301) is in phase II (for certain neuroblastoma patients) and is also clinically tested against melanoma. Also in the clinical stage is a liposomal formulation of recombinant human superoxide dismutase (APN201) to prevent or treat skin damage due to radiation treatment in cancer. A further clinical project (APN01) was licensed to GSK in 2010. It is currently in phase II, recruiting patients with acute lung injury (ALI), and has considerable potential in other disease areas.
Products Products
Indication
Stage of development
—— APN311
Neuroblastoma
Phase III
—— APN301
Neuroblastoma, melanoma
Phase II
—— APN01
ALI
Phase II
—— APN201
Inflammatory skin conditions
Phase II
—— APN401
Solid tumors
Preclinical
—— APN411
Solid tumors
Under development
Company Profile Founded: 2003 Legal Form: AG Employees: 23
Hans Loibner, CEO Apeiron Biologics
Management Team
Technology
Market
—— Apeiron’s lead project targets an antigen (GD2) that is present on other cancers (e.g. sarcomas, small-cell lung cancer) as well. The first targeted line extension is melanoma.
—— Cancer remains an area with a very high unmet medical need. Neuroblastoma is an orphan indication that affects mainly infants. There is no sufficiently efficacious therapy on the market.
CEO: Hans Loibner COO: Manfred Schuster CFO: Lukas Kadawy Public Funding
26
aws Seed, Double Equity, ZiT, FFG, Wirtschaftskammer Österreich (Austrian Federal Economic Chamber): Not disclosed Private Funding
APEIRON Biologics AG Campus-Vienna-Biocenter 5 1030 Vienna, Austria +43 1 865 65 77 apeiron@apeiron-biologics.com www.apeiron-biologics.com
Not disclosed
Biotech / Pharma – 27
APEPTICO
Products
is a privately held biotechnology company based in Austria, developing peptide-based products targeting chronic and life-threatening diseases such as respiratory failure, pulmonary edema, acute lung injury, lung transplantation, ischemia reperfusion injury, and high-altitude edema. The peptide molecules correspond to validated, pharmacodynamic active structures and domains of well-known proteins and biopharmaceuticals. By concentrating on synthetically produced protein structures, APEPTICO avoids general risks associated with gene and cell technologies. APEPTICO makes use of its technology platforms PEPBASE™ and PEPSCREEN™ to significantly reduce cost and to shorten time to market.
Technology
Market
—— Respiratory failure, pulmonary edema, acute lung injury, lung transplantation, ischemia reperfusion injury, high-altitude edema —— We collect molecular, structural, biological, and medical data of well-characterized proteins and biopharmaceuticals in our proprietary database, PEPBASE. —— Identification of a bioactive moiety is the first step of PEPSCREEN, our fast-track product development pathway. —— All molecules are protected by patents and fully owned by APEPTICO.
—— The therapeutic market for acute lung failure was worth $ 620M in 2011 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 1.3% to reach $ 681M by 2019. —— The therapeutic market data are for US, France, Germany, Italy, Spain, UK, and Japan. —— Total population of 750M.
28
Products
Indication
Stage of development
—— AP301-IH
Respiratory failure
Phase II
—— AP301-IRI
Lung transplantation
Phase II
—— AP301-PN
Lung infection
Phase II
APEPTICO’s lead compoud: AP301 Company Profile Founded: 2008 Legal Form: GmbH Employees: 5 Management Team CEO: Bernhard Fischer CSO: Rudolf Lucas Public Funding aws PreSeed: € 100,000 FFG: € 3.91M Private Funding
APEPTICO Forschung und Entwicklung Mariahilferstr. 136, Top 1.15 1150 Vienna, Austria +43 664 1432919 b.fischer@apeptico.com www.apeptico.com
€ 4.5M
Biotech / Pharma – 29
BDS Pharma
Products
is a drug delivery company founded in June 2012. The company’s mission is to develop and commercialize a novel drug delivery platform that combines the use of conventional polymer drug delivery vehicles and approved drugs to be implanted directly within the Central Nervous System (CNS). The polymeric delivery devices can provide tailored release of appropriate doses of drugs for the given clinical population within the focal site in the impacted brain without causing systemic side effects. Technology
Market
—— Our lead product “Nicaplant” (patent pending) is a brain implant designed to prevent and treat cerebral vasospasm following aneurysmal subarachnoid hemorrhage (aSAH) and other traumatic brain injuries. Cerebral vasospasm is a leading cause of permanent brain damage and death following aSAH. —— The manufacturing process is a commercially scalable melt extrusion process applying Nicardipine and a PLGA polymer matrix. —— The patent for Nicaplant has been filed for key markets including USA, Europe, Russia, South Africa, Brazil, Australia, Hong Kong, and Japan. —— BDS’s technology platform is designed to cover additional therapeutic areas including oncology, other neurodegenerative disorders where site-specific delivery provides patient benefit, and gene therapy.
—— Treatment preventing cerebral vasospasm addresses a serious unmet medical need with a prevalence of approx. 10 patients / 100,000 people —— Expected to qualify as a rare disease to be eligible for an Orphan Drug status by European and US regulators (EMA, FDA) —— Our strategy to use conventional polymer drug delivery vehicles and approved drugs reduces development risk and cost, and increases speed to market.
30
Products
Indication
Stage of development
—— Nicaplant
Treatment and prevention of cerebral vasospasm
Phase II
Illustration of Nicaplant application
Company Profile Founded: 2012 Legal Form: GmbH Employees: 1 Management Team CEO: Bernd Pöcheim
BDS Pharma GmbH
Public Funding
Marburger Kai 47 8010 Graz, Styria, Austria +43 664 356 038 9 office@bds-pharma.at www.bds-pharma.at
aws Seed: € 500,000 Private Funding Not disclosed
Biotech / Pharma – 31
Diagnosia
Products
was founded by a group of physicians and software developers and is based in Vienna, Austria. The company is an independent European source for medical drug information provided through a sophisticated application that includes a broad variety of functions and allows fast access to relevant, synchronized professional information for doctors. In Austria, doctors don’t have relevant medical drug information when needed and no suitable user interface to interact with. Therefore, we provide up-to-date professional information by partnering with various governmental medical agencies all over Europe.
Technology
—— Diagnosia Index: advanced crossdevice drug information system available on Web, iPad, iPhone and Android. This state-of-the-art web application uses authorized public data sources and has plenty of add-on features.
—— Diagnosia Check: Diagnosia Check is available as an iOS app that provides an up-to-date and evidence-based drug-drug and drug-food interaction tool for health care professionals.
Market Company Profile
—— Our algorithm automatically converts package leaflets and professional information from pdf into digital format. —— Semantic analysis and machine learning of source files, paired with pdf-converting technology. —— The information is available in 14 languages on mobile devices as well as on your personal computer. —— Entity extraction through machine learning approach —— Lean and efficient process to publish data 32
—— $ 1.08bn total US investments in digital health in 2012 —— $ 320bn total health care system spending on medicines in 2011 (USA) —— $ 6.9bn projected mHealth revenue in Europe by 2017 —— 73% more investments in digital health made in 2012 than 2011 —— Digital health is a national game: each country has different technical implications regarding its drug data structure.
Founded: 2011 Legal Form: GmbH Employees: 15
Diagnosia platform
Management Team CEO: Marco Vitula CTO: Christoph Lupprich Head of Product: Lukas Zinnagl Public Funding aws Seed: € 150,000 FFG: € 300,000 Private Funding
Diagnosia Internetservices GmbH Fillgradergasse 7/3 1060 Vienna, Austria +43 129 566 05 office@diagnosia.com www.diagnosia.com
€ 235,000
Biotech / Pharma – 33
Dutalys
Products
is a private Austrian antibody technology company, committed to developing superior treatments for complex and multifactorial diseases, including cancers and inflammatory diseases. Dutalys has developed the DutaMab™ platform technology, to provide the only class of bispecific antibody molecules that retain all the advantages of state-ofthe-art monospecific antibody therapeutics. The benefits of DutaMabs™ include high affinity against all classes of drug targets, convenient manufacturing fully equivalent to monospecific antibody drugs, and outstanding stability.
34
Indication
Stage of development
—— DutaMab™
Ultra-stable fully human bispecific IgG molecules
Preclinical
—— DutaFab™
Ultra-stable fully human bispecific Fab fragments
Preclinical
—— DutaLib™
Synthetic libraries of ultra-stable fully human bispecific antibodies
Preclinical
Market —— The global sales of therapeutic antibodies was USD 52 billion in 2010. —— The majority of growth in global drug sales in the next five years is expected to come from therapeutic antibodies.
Technology —— While monospecific antibody drugs represent an important medical and commercial success, complex and multifactorial diseases such as cancers and inflammatory diseases are often not adequately treated by addressing a single drug target in patients. To address this unmet medical need, the pharmaceutical and biotech industries have increasingly developed novel antibody formats, including bispecific antibodies directed against two drug targets. —— Previous bispecific antibody formats suffer from serious limitations, especially in the areas of stability, manufacturability, and discoverability. —— DutaMabs™ comprise two independent, non-overlapping paratopes within the natural CDR regions of a
Products
fully human antibody, which can be independently selected and optimized in a robust and rapid manner to bind any two targets with high affinity and specificity. —— DutaMabs™ comprise only one normal fully human heavy-chain polypeptide and one normal fully human light-chain polypeptide and are extremely efficiently produced using all standard antibody manufacturing platforms. —— DutaMabs™ are based on fully human antibody scaffolds with world-record biophysical stability, and routinely achieve best-in-class thermal stability as well as excellent chemical and in vivo stabilities. Dutalys technologies are protected by five independent patent families. Dutalys’ freedom to operate has been independently verified.
—— The pharmaceutical industry invested USD 18 billion in 2010 into R&D of biologics and is increasingly turning to external sources for innovation.
Company Profile Founded: 2010 Legal Form: GmbH Employees: 8
DutaMab technology
Management Team CSO, Cofounder: Roland Beckmann Managing Director: Mabel Mak Business Adviser: Thomas von Rüden VP Research: Kristian Jensen Public Funding aws PreSeed: € 100,000 aws Seed: € 1M Others (FFG, ZIT, INiTS): € 655,000 Private Funding
Dutalys GmbH Muthgasse 11/2/3 1190 Vienna, Austria +43 1 9971832 office@dutalys.com www.dutalys.com
Not disclosed
Biotech / Pharma – 35
Eucodis Bioscience
Products
delivers high-performance enzyme solutions for highly specific applications in the biopharma, fine chemicals, and cosmetics industries. With a portfolio of over 50 enzymes, including innovative lipases, beta-lactamases, peroxidases, and other enzymes, Eucodis Bioscience has a proven track record of providing customized enzyme solutions. Eucodis specializes in setting up optimized bioprocesses for scale-up and manufacturing recombinant proteins under ISO 9001.
—— LacBusterTM : Innovative formulations of beta-lactamases for sterility testing and environmental monitoring in antibiotics production. —— Lipases: Panel of over 25 unique lipases carefully selected and engineered for applications in the chemical, pharmaceutical and food & feed industries. The enzymes show superior activity in multiple applications, such as the production
Technology
Market
—— Enzyme Engineering: Proprietary in vivo recombination, gene shuffling, and other technologies for protein and enzyme engineering. —— Fermentation Technologies: Most advanced expression systems using E. coli, P. pastoris, B. subtilis, and Aspergillus oryzae for scalable production of enzymes and other proteins under ISO9001:2008 quality standards. —— Conjugation of Antibodies: A novel linker technology (CTAT technology) designed to covalently attach a recombinant antibody or antibody fragment to a therapeutic drug through a specific enzymatic reaction. This directed conjugation method is site-specific and does not interfere with the antigen binding site. —— Applications: Antibody-drug conjugates (ADCs); labeling of recombinant proteins, antibodies, or antibody fragments.
—— Industrial enzymes for catalytical processes in the pharmaceutical, cosmetics, chemical, and food & feed industries. —— LacBusterTM targets a niche market with an annual sales volume of 20 million EUR. —— The ADC market is estimated to reach $ 5.8bn by 2016.
36
of nutritionally valuable fats and oils, emollient ester synthesis and API production —— Peroxidases, Phospholipases D: Libraries for industrial applications —— Services: Solutions for Biocatalysis and protein production including bioprocess development, enzyme identification, protein engineering, up to industrial-scale manufacturing of enzymes and proteins as CMO.
Eucodis product Company Profile Founded: 2007 Legal Form: GmbH Employees: 19 Management Team CEO: Karl Hübler Technical Director: Jan Modregger Public Funding aws Seed: € 500,000 Others (FFG, WWFF, WAFF, ZIT, EU): € 1.25M Private Funding
Eucodis Bioscience GmbH Viehmarktgasse 2a/2OG 1030 Vienna, Austria +43 1 8900 804 0 office@eucodis.com www.eucodis.com
€ 8.87M
Biotech / Pharma – 37
EveliQure Biotechnologies aims to develop efficacious vaccines to reduce the high burden of diarrheal diseases among travelers and young children living in resource-poor countries. It is widely accepted that prophylactic vaccination would be the most effective way to address this high unmet medical need; yet, no vaccines are currently available.
Technology
Market
—— EveliQure has developed a novel vaccine technology platform based on a live attenuated Shigella strain. The platform is amenable for the heterologous expression of diarrheal antigens and can therefore provide protective immunity against multiple pathogens. —— EveliQure’s first vaccine candidate, SHIGETECTM is intended to be developed as a drinkable (oral) vaccine. It contains the attenuated Shigella vaccine strain that expresses ETEC antigens known to induce protective immunity when expressed in appropriate forms. —— EveliQure filed a patent to protect the technology platform and the first vaccine candidate.
—— The market demand for ShigETECTM comes from three target groups: travelers from industrialized countries to developing countries; military personnel (US & NATO, etc.) stationed in developing countries; NGOs and governments of the developing countries where Shigella and ETEC infections are endemic. —— Global demand is estimated to reach approximately 100 million doses per year, with revenues peaking around $ 600M 12 years after launch. —— No vaccines currently available.
38
Products Products
Indication
Stage of development
—— EveliQure Vaccine Technology Platform
Diarrheal diseases
Preclinical
—— SHIGETEC vaccine
Shigella, ETEC
Preclinical
Company Profile
EveliQure technology
Founded: 2012 Legal Form: GmbH Employees: 2 Management Team MD: Zoltán Dobai CSO: Tamás Henics Public Funding aws PreSeed: € 190,000 Private Funding
EveliQure Biotechnologies GmbH Helmut-Qualtinger-Gasse 2 1030 Vienna, Austria +43 680 243 447 9 office@eveliqure.com www.eveliqure.com
€ 30,000
Biotech / Pharma – 39
Evercyte
Products
is a provider of relevant preclinical model systems that will enable the acceleration of drug discovery and development by reducing development time and cost. These cellular model systems are based on primary cells that are immortalized either without altering key functional characteristics or by using adult stem cells and urine-derived, induced pluripotent stem cells.
Technology
Market
—— Preclinical model systems, drug research and development, screening, toxicology, primary-like immortalized cell lines, adult stem cells, induced pluripotent stem cells, differentiation of cells, contract research, urine-derived cells —— Immortalization of human cells using telomerase and/or viral oncogenes —— Production of induced pluripotent stem cells from human-urine-derived cells. The non-invasive nature of this technology allows easy donor recruitment —— Pharmacocellomics: production of panels of immortalized cell lines of different donors and/or different tissues for better estimating effects of substances on the general population
—— The global cell-based assay’s market will reach $ 1.5bn in 2017, according to a new report by Global Industry Analysts, Inc. —— Industry: Biotech – preclinical model systems, toxicology model systems for pharma, chemical, and cosmetic industry —— Clients: Companies from pharmaceutical and biotechnological industries, chemical and cosmetic industries, environmental toxicology, CROs
40
—— Immortalized cell lines: Evercyte offers immortalized primary human cells and/ or cell panels of different donors and/or different tissues for preclinical target and drug discovery, drug development, and quality control during drug manufacturing.
—— Customer-tailored cell lines: Evercyte offers services for the development of (immortalized) customer-tailored cells and cell-based assays. —— Cell-based assays and research & development
HUVEC TERT2 endothelial cells Company Profile Founded: 2011 Legal Form: GmbH Employees: 10 Management Team CEO, co-founder: Otto Kanzler CSO, co-founder: Johannes Grillari Co-founder: Regina Grillari Public Funding aws PreSeed: € 150,000 Private Funding
Evercyte GmbH Muthgasse 18 1190 Vienna, Austria +43 699 18162222 (scientific issues) +43 664 4227861 (business issues) office@evercyte.com www.evercyte.com
Not disclosed
Biotech / Pharma – 41
F-star
Products
develops bispecific antibody products to improve the treatment of serious diseases. F-star is the only biopharmaceutical company creating bispecific antibodies by modifying the constant region of an antibody. Our Modular Antibody Technology offers unprecedented ease in the development and manufacturing of bispecific antibody products.
Technology
Market
—— Our robust Modular Antibody Technology enables the rapid design and creation of large panels of bispecific antibodies. These “2-in-1” drugs offer the potential for powerful synergistic benefits not achievable by co-administration of individual drugs. —— We first modify the constant region of an antibody to bind to a therapeutic target of interest (an “Fcab™” ); then we utilize our modular recombination approach to create genuine bispecific monoclonal antibodies that bind two different antigens at the same time (“mAb2™”). —— The simple “mix-and-match” capability of F-star’s highly efficient discovery engine creates virtually limitless bispecific product opportunities. —— F-star’s IP portfolio provides exclusivity around its Fcab™ and mAb2™ technologies and their applications.
—— Total biologics sales expected to grow by 45% between 2010 and 2016 from $ 130bn to $ 192bn —— Top 3 selling global pharmaceuticals projected to be biologics in 2016 —— Targeted biologics represent the most significant market segment within biologics with > 50% of total biologics revenue today and double-digit annual growth over the past decade
42
Products
Indication
Stage of development
—— H561-4
Solid tumors
Preclinical
Company Profile Founded: 2006 Legal Form: GmbH Employees: 32
CEO: John Haurum
Management Team CEO: John Haurum COO: Jane Dancer VP Discovery: Mihriban Tuna VP Biological Products: Haijun Sun Executive Program Director: Kate Seaber Public Funding aws: € 1.5M FFG: € 1.5M INITS: € 60,000 Private Funding
F-star GmbH Schwarzenbergplatz 7 1030 Vienna, Austria +44 122 349 740 0 office@f-star.com www.f-star.com
€ 30M
Biotech / Pharma – 43
GAT Microencapsulation is an agrochemical company specializing in the development, registration, and manufacture of advanced plant protection products. GAT has developed innovative and cost-effective technologies for the formulation of agrochemicals, most notably microencapsulation. The company’s intellectual property in these technologies is based on a complex combination of international patents.
Services Services
Description of Service
—— Service 1
Contract research under GLP
—— Service 2
Manufacturing
—— Service 3
Regulatory services
Company Profile Founded: 1999 Legal Form: AG Employees: 50
GAT Headquarters
Management Team
Technology/Innovation
Market
CEO: Barbara Gimeno CTO: Miguel Gimeno CFO: Wilfried Wiesinger Public Funding
—— Formulation/regulatory development —— PCT patents on CS and OD technology —— Global licensing, distribution, and service agreement with FMC Corporation USA 44
—— Global market size $ 50bn —— European agrochemical market $ 11.5bn in 2012 —— Annual growth rate 5.4% p.a. till 2018
aws Seed: Not disclosed aws others: Not disclosed Private Funding
GAT Microencapsulation AG Gewerbezone 1 2490 Ebenfurth, Lower Austria, Austria +43 262 453 922 0 gat@microencapsulation.at www.microencapsulation.at
100%
Biotech / Pharma – 45
Haplogen
Products
Haplogen’s mission is to improve human health by combating infectious disease. Employing proprietary genetics technology to identify host factors, Haplogen is building a pipeline of therapeutic programs in the area of viral diseases. Its most advanced program develops antiviral substances against rhinovirus.
Technology
Market
—— Antiviral therapies are constantly challenged by rapidly emerging resistant strains. —— Targeting a host factor places a far higher barrier for resistance and can enable the development of more powerful drugs. —— Haplogen’s technology delivered a pipeline of first-in-class host factor targets that are used to develop antiviral drug candidates. —— Haplogen holds exclusive licenses and has applied for several proprietary antiviral patents.
—— Most viral diseases have no therapy available, and patients receive symptomatic treatments. —— Rhinovirus infects adults on average four times a year with no therapy available. Globally, this represents a multibillion-dollar market. —— Several acute viral diseases have no therapy available and each represents a potential billion-dollar market —— Haplogen develops therapeutic agents up to clinical candidates. We then outlicense or develop them in partnerships with biotechnology and pharmaceutical companies.
46
Products
Indication
Stage of development
—— PT1
ICD B34.8 Common cold
Preclinical phase
—— Human knock out cell lines
Research tools
Marketed
Company Profile Founded: 2010 Legal Form: GmbH Employees: 10
Haplogen technology
Management Team CEO: Georg Casari Head of Science: Tilmann Bürckstümmer Public Funding aws Seed: Not disclosed Others (FFG, ZIT): Not disclosed Private Funding
Haplogen GmbH Campus Vienna Biocenter VBC5 1030 Vienna, Austria +43 1 916 552 210 office@haplogen.com www.haplogen.com
Not disclosed
Biotech / Pharma – 47
Innovacell Biotechnologie is a privately held biotechnology company based in Innsbruck, Austria, with a focus on incontinence. The company focuses on the clinical development and commercialization of autologous (i.e. patient’s own cells), minimally invasive cell therapies. INNOVACELL’s personalized products are potentially curative one-off treatments, which re-establish functionality of sphincter muscles in patients, e.g. with stress urinary incontinence (SUI) or fecal incontinence (FI).
Technology
Market
—— ICES13 is the autologous tissue engineering product for the treatment of patients suffering from stress urinary incontinence (SUI). —— Innovacell has completed recruitment for the multicenter Phase III clinical trial of ICES13 in Europe. Marketing authorization in the EU is expected to be available by the end of 2014. —— ICEF15® is the autologous tissue engineering product for the treatment of patients suffering from fecal incontinence. —— Following successful proof-of-concept studies for ICEF15®, Innovacell will start a multicenter Phase IIb trial in Q3/2013. Regulatory approval in the EU is expected to be available in 2018.
—— ICES13® addresses a market of approximately 23 million patients suffering from SUI in the top seven global markets including 2.2 million new patients every year, for which ICES13® could be the treatment of first choice. —— Top 7 global markets for fecal incontinence are estimated to contain 2.5 million patients in need of therapy.
48
Products Products
Indication
Stage of development
—— ICES13
Stress urinary incontinence
Phase III
—— ICEF15
Fecal incontinence
Phase IIb
Company Profile Founded: 2000 Legal Form: AG Employees: 23
Innovacell technology
Management Team CEO: Ekkehart Seinhuber CSO: Rainer Marksteiner Public Funding aws Seed: € 400,000 aws TFP guarantees: € 2.7M Private Funding
Innovacell Biotechnologie AG Mitterweg 24 6020 Innsbruck, Austria +43 512 573 680 office@innovacell.com www.innovacell.com
Not disclosed
Biotech / Pharma – 49
INOXIA Lifesciences is an innovative, newly founded biotech company that specializes in the field of drug development with human peroxidase as the main target. Peroxidases are innate immune system enzymes, which are responsible for chronic inflammatory and neurodegenerative diseases. Selective potential inhibitors form the basis for new medication to be used for the treatment of asthma, COPD, endometriosis, and bowel diseases such as ulcerative colitis to mention a few. The company is developing small molecule candidates for entry into clinical trials.
Technology
Market
—— Local accumulation of eosinophils causes chronic inflammatory processes through the release of eosinophil peroxidase (EPO). —— INOXIA’s innovation is the development of selective inhibitors against the enzyme EPO, in order to prevent and reduce the progress of chronic inflammation of several diseases. There are initial promising results regarding the efficacy of EPO inhibitors in asthma animal models. —— WO2011091461A1: The patents comprise possible derivatives of the lead substance AW/EPO/003 for several indications.
—— The global market for asthma medication covers $ 33bn (annual growth rate 4.4 %) and for ulcerative colitis $ 1.7bn (growth rate 8.5%). —— Typical asthma pharmaceuticals are corticosteroids and bronchodilators. No inhibitor against eosinophil peroxidase for the treatment of inflammatory process is currently on the market. —— Blockbuster scenario for asthma opens up promising perspectives for investors.
50
Products Products
Indication
Stage of development
—— AW/EPO/003
Asthma
Preclinical
—— AW/EPO/PD01
Colitis
Preclinical
—— AW/EPO/XXX
Endometriosis
Under development
Target: EPO active site + inhibitor Company Profile Founded: 2011 Legal Form: GmbH Employees: 4 Management Team CEO: Andreas Kubin CSO: Martina Zederbauer CFO: Georg Jessner Public Funding aws PreSeed: € 200,000 Others (FFG, ZIT): € 200,000 Private Funding
INOXIA Lifesciences GmbH Erlgasse 48 1120 Vienna, Austria +43 1 810 536 6 akubin@inoxia.at www.inoxia.at
€ 300,000
Biotech / Pharma – 51
Inte:Ligand
Services
is a research-based software development and consulting company that helps clients and partners in the life sciences industry to prioritize and de-risk novel bio-active molecules for development.
Technology/Innovation
Market
—— Inte:Ligand’s software products support scientists in the life sciences industry to select the best-suited candidates for biological evaluation and development. With LigandScout, the most userfriendly software for advanced pharmacophore modeling, and by using accurate and rapid in silico screening, the most promising molecules can be selected and optimized. With the PharmacophoreDB, compounds can be de-risked for further development as drug candidates.
—— global life sciences market —— pharma, biotech, agro, nutraceutical, and cosmetic industry
52
Services
Description of Service
—— LigandScout 3.0
Fully integrated platform for accurate virtual screening of candidates based on 3D chemical feature pharmacophore models
—— Contract Research
3D Pharmacophore Development Virtual Screening Generation of Customized Virtual Libraries Lead Structure Optimization
Sharon D. Bryant; Inte:Ligand CEO Company Profile Founded: 2003 Legal Form: GmbH Employees: 11 Management Team CEO: Sharon D. Bryant CSO: Gerhard Wolber Public Funding aws Seed: Not disclosed Others (FFG, EC FP7): Not disclosed
Inte:Ligand Software-Entwicklungsund Consulting GmbH 2344 Maria Enzersdorf, Lower Austria, Austria Clemens Maria Hofbauer-Gasse 6 +43 699 150 752 52 office@inteligand.com www.inteligand.com
Biotech / Pharma – 53
Lexogen
Products
is an ambitious biotech start-up based in Vienna, Austria, developing unique proprietary expression profiling technologies. Founded in 2007, Lexogen currently has 26 employees and is funded by both private capital and public funds, in particular by Austrian Research Promotion Agency FFG, Austria Wirtschaftsservice aws, INiTS, and Wirtschaftsagentur Wien.
Technology/Innovation
Market
—— Lexogen specializes in the development of novel RNA sequencing library preparation methods. The main assets are a series of RNA segregation systems to obtain different RNA fractions of interest. The subsequent transformations into libraries are compatible with any massive parallel sequencing technologies. —— Lexogen has a proprietary technology portfolio that is protected by a growing number of patent applications. Currently, 9 patent applications have been made in the areas of molecular biology, process and nanotechnology, and bioinformatics.
—— The world Next Generation Sequencing market includes instruments, consumables, and related services and was estimated in 2012 as $ 1bn (CAGR 17%). USA has the biggest share of the market, 51.8% (CAGR 22.7%), Europe has 31.1% (CAGR 21.1%), and Asia has 14% (CAGR 26.8%). —— RNA sequencing constitutes 25% of the overall NGS market. The key NGS platforms are provided by Illumina (San Diego, CA, United States of America) and Life Technologies (Carlsbad, CA, United States of America).
54
Product
Description of Product
—— SENSE
SENSE is a complete strand-specific mRNA-Seq library preparation kit for accurate gene expression profiling, transcriptome sequencing, and discovery, assuring the precise quantification of antisense transcripts and overlapping genes.
—— SPLIT
The SPLIT RNA Extraction kit enables a fast and highly efficient extraction of RNA that is free of genomic DNA contamination. The RNA can be recovered as total RNA or split into a large and a small RNA fraction, facilitating the analysis of, for example, mRNA and miRNA from the same sample.
—— SQUARE (service)
SQUARE enables hypothesis-free identification and quantification of all known and unknown full-length transcripts. The technology selectively amplifies transcript variants – including splice variants – in a scalable number of so-called matrix fields. Following NGS, transcript hypotheses can be generated reliably for the reduced variant complexity within the matrix fields. Together with nucleotide-level start- and end-site tagging, SQUARE enables the detection of known and the discovery of novel transcript variants. Differential gene expression analyses can be performed on the level of transcript variants, providing investigators with more significant information about transcriptomic differences.
Company Profile
The Lexogen Service
Founded: 2007 Legal Form: GmbH Employees: 26 Management Team CEO: Alexander Seitz CSO: Torsten Reda Public Funding aws PreSeed: € 50,000 aws Seed: € 1M Others (FFG): € 3.85M
Lexogen GmbH Campus Vienna Biocenter 5 1030 Vienna, Austria +43 1 345 1212 office@lexogen.com www.lexogen.com
Biotech / Pharma – 55
Marinomed
Products
is focused on the development of innovative therapies against respiratory diseases (such as common cold and influenza) based on an innovative anti-viral respiratory technology platform called Mavirex. Safety and effectiveness of the Mavirex platform have been proven in three clinical trials in adults and children and by its marketed anti-viral OTC common cold and influenza portfolio. Furthermore, Marinomed has a pipeline of proprietary compounds in allergy and autoimmune diseases that are in development.
Technology
Market
—— Mavirex is a powerful platform for the development of products against vira infections such as common cold and influenza. Four products have been approved for marketing in the EU and abroad. Additional Mavirex-based products will hit the market within the next two years. —— A strong product pipeline boasts a novel immunomodulator MAM-08.101, the anti-allergic MAM-06.301, and a novel class of anti-infectives.
—— The world market for cold, cough, and sore throat remedies is projected to exceed $ 22.2bn by the year 2015. This is primarily driven by a rise in the population suffering from cold, cough, and sore throat symptoms, and the introduction of effective medications. —— Market proof of concept: Marinomed’s lead product, an innovative anti-viral common cold nasal spray containing Carragelose®, a polymer of the Mavirex platform, is outlicensed to Boehringer Ingelheim, covering 55 countries in Europe, Russia and CIS, South America, parts of Asia, and Australia. 29 countries are licensed to local partners. —— The product is already marketed in 13 countries worldwide.
56
Products
Indication
Stage of development
—— Anti-viral OTC Portfolio
Common cold, influenza
Marketed
Company Profile Founded: 2006 Legal Form: GmbH Employees: 26
Coldamaris Product
Management Team CEO: Andreas Grassauer CSO: Eva Prieschl-Grassauer Head Development: Angelika Bodenteich Head Finance: Helmut Baranyovszk Head Business Development: Johanna Uhlmann Head Research: Martina Kurz Public Funding Not disclosed Private Funding
Marinomed Biotechnologie GmbH Veterinärplatz 1 1210 Vienna, Austria +43 1 250 774 460 office@marinomed.com www.marinomed.com
Not disclosed
Biotech / Pharma – 57
Mucokinetica
Products
is an epithelial biology drug discovery and development company. Our lead product is an orphan drug treatment for cystic fibrosis lung disease. By reducing excessive sodium absorption in the airways, we aim to deliver disease-modifying, long-duration relief from the adverse effects of the major driver of CF chronic lung disease.
Technology
Market
—— MKA 104 is a small-molecule drug re-purposing opportunity with reduced risks of failure in development compared to NCEs. —— MKA 104 is a solution to the problem of excessive sodium absorption in the airways with disease-modifying potential for CF. —— MKA 104, through inhalation, inhibits activation of sodium channel proteins in the airway surface epithelium and provides long-duration reduction of and relief from the excess sodium absorption that is the major driver for chronic lung disease in CF. —— IP Status: MKA 104 method of use patents; MKA 104 designated for orphan drug development in EU
—— 80,000 CF patients worldwide —— CF patient number annual growth 3 to 6% —— MKA 104 targets all CF patients, all CF genotypes —— CF major markets are EU and US (CF is extremely rare in Japan) —— CF therapeutic market value $ 1.1bn (Global Data Report 2010); estimated to grow to $ 2.1bn by 2017 —— Further market opportunities: COPD; Non-CF bronchiectasis
58
Products
Indication
Stage of development
—— MKA 104
Cystic fibrosis
Under development
—— MKA 109
Women’s health – vaginal dryness
Under development
Company Profile Founded: In foundation Employees: 2
Ion channel pharmacology studied in pig airway organ explants
Management Team CEO/CSO, co-founder: Rod Hall CMO, co-founder: Peter Cole Public Funding aws PreSeed: € 200,000 Private Funding
Mucokinetica Schiffmühlenstrasse 47 / 330 1220 Vienna, Austria +43 669 182 693 79 enquiries@mucokinetica.com www.mucokinetica.com
€ 20,000
Biotech / Pharma – 59
Origimm
Products
is a young, ambitious Austrian biotech company striving to become a market leader in protective antigen discovery. Using its proprietary ProVaDis® technology platform, Origimm overcomes the challenges in vaccine and immune therapy development with early focus on protective efficacy of antigens in the context of human disease. This translates into a rapid selection of best, most-protective candidates with a significantly improved success in clinical trials. Origimm is developing the first therapeutic vaccine for treatment of acne vulgaris; the disease with enormous market potential, afflicting 85% of teenagers and more than 10% of adults.
Technology —— Currently 85% of all vaccine candidates that enter Phase I clinical trial, fail to be approved for the market. More than 1/3 of all the clinical failures can be traced back to the suboptimal selection of vaccine antigens. The main challenge is predicting protective efficacy of antigen candidates, because current methods do not incorporate tests for protective efficacy during early stages of antigen screening. —— ProVaDis® (Protection-based Vaccine Discovery) technology overcomes these challenges by incorporating protective efficacy testing in the very early stage of antigen screening, ensuring the selection of the most protective vaccine antigens. 60
Products
Indication
Stage of development
—— Therapeutic vaccine
Acne vulgaris
Preclinical
Market —— The global vaccine market is expected to increase by more than 100% from $ 24bn in 2009 to $ 56bn in 2016. Vaccines are becoming increasingly important as revenue generators within the portfolios of the key pharma players. —— The global acne treatment market is estimated to reach revenues of $ 3.1bn by 2017 at a Compound Annual Growth Rate (CAGR) of 0.7% at ~$ 3bn.
Sanja Selak, CEO Origimm Company Profile Founded: 2012 Legal Form: e.U. Employees: 3 Management Team CEO: Sanja Selak CSO: Sanja Selak CFO: Thomas Fischer Public Funding aws PreSeed: € 200,000 ZIT: € 420,000 INITS: € 30,000+ Private Funding
Origimm e.U. Leberstrasse 20 1110 Vienna, Austria +43 676 448 4825 office@origimm.com www.origimm.com
Series A/2014
Biotech / Pharma – 61
Panoptes Pharma
Products
“Vision is our Mission”: Panoptes develops small-molecule-based therapies for autoimmune- and viral-caused indications in ophthalmology with high unmet medical needs. Panoptes’ clinical candidate PP-001 is currently in preclinical development for autoimmune uveitis and adenoviral conjunctivitis. PP-001 will provide much-needed treatment options that are more efficacious and more tolerable and therefore provide a better quality of life for patients with these eye diseases.
Technology
Market
—— PP-001 is a highly specific nanomolar inhibitor of an essential enzyme of the de novo pyrimidine pathway, inhibiting the expression of IFN- and IL-17, two hallmark cytokines responsible for autoimmune uveitis. —— PP-001 was shown to be efficacious in 2 different animal models for uveitis. —— PP-001 reduces the host cell pyrimidine pool, inhibiting the replication of adenovirus serotypes that cause the highly contagious viral form of conjunctivitis. —— Unique physicochemical properties of PP-001 allow systemic and local administration. —— Panoptes owns about 60 patents and patent applications worldwide, protecting PP-001 and its use.
—— Addressable market for both indications is > $ 700M each. —— For conjunctivitis, no anti-viral drug is on the market. —— Uveitis is currently treated with corticosteroids with severe adverse effects. —— PP-001 has the potential to be developed for further indications like dry-eye syndrome, psoriasis, different viral infections, etc.
62
Products
Indication
Stage of development
—— PP-001
Uveitis
Preclinical
—— PP-001
Viral conjunctivitis
Preclinical
Franz Obermayr, CEO, & Stefan Sperl, COO
Company Profile Founded: 2013 Legal Form: GmbH Employees: 2 Management Team CEO: Franz Obermayr COO: Stefan Sperl Public Funding
Panoptes Pharma Ges.m.b.H. Parkring 10 1010 Vienna, Austria +43 664 8557369 info@panoptes-pharma.com www.panoptes-pharma.com
aws Seed: € 1M
Biotech / Pharma – 63
PDC Biotech
Products
is a biotechnology company developing novel compounds for the treatment of preterm labor and primary dysmenorrhea, two areas of significant unmet medical need and large market potential. Excessive uterine contractility in both conditions is mediated by prostaglandin F2 (PGF2 ). At the core of the company is a unique, proprietary series of PGF2 receptor antagonists. Technology
Market
—— Preterm labor is defined as regular contractions associated with cervical changes occurring before 37 weeks of gestation. —— Primary dysmenorrhea is characterized by cramping pelvic pain caused by frequent and prolonged uterine contractions that decrease blood flow to the myometrium. —— PDC’s lead compound, PDC31 is a synthetic octapeptide that is a potent, non-competitive, selective antagonist of the PGF2 receptor. —— In vitro models have shown that PDC31 inhibits spontaneous and PGF2 -induced uterine contractions; in vivo animal models have shown that PDC31 significantly prolongs pregnancy. —— In a first-in-human study, administration of PDC31 was associated with a reduction in intrauterine pressure as well as with a dose-dependent relief of dysmenorrhea pain. —— PDC Biotech has licensed exclusive worldwide rights to a family of FP receptor antagonists from Theratechnologies Inc. (www.theratech.com).
—— Preterm birth is a major public health care issue; approximately one in ten babies in Europe is born prematurely. —— In the US, the reported rates of preterm births are among the highest in the world. In 2008, nearly 500,000 infants (12.3%) were born preterm. —— Annual societal economic burden associated with preterm birth in the US was estimated at $ 26.2bn, $ 52,000 per infant born preterm. —— Health care costs are about 10 times greater for preterm than for term infants. —— Primary dysmenorrhea is a disabling condition found in approx. 10–15 % of women of childbearing age; it is estimated to account for 600M lost work hours ($ 2bn in lost productivity) annually in the US alone.
64
Products
Indication
Stage of development
—— PDC31
Preterm labor
Phase I completed
—— PDC31/PDC41
Primary dysmenorrhea
Phase I completed
Novel compounds for the treatment of preterm labor and primary dysmenorrhea
Company Profile Founded: 2008 Legal Form: GmbH Employees: 3 Management Team Managing Director: Roman Goetz Public Funding aws Seed: € 1M ZIT: € 516,654 Private Funding
PDC Biotech GmbH Kärntner Ring 10/12 1010 Vienna, Austria +43 189 000 771 0 office@pdcbiotech.com www.pdcbiotech.com
€ 6.23M
Biotech / Pharma – 65
Procomcure Biotech The need addressed by Procomcure is the dearth of novel antibacterial agents. The company has now identified a new class of antimicrobial compounds with activity against clinically important antibiotic-resistant bacterial infections, and has technology to address modes of antibiotic action and development of resistance. To advance drug development, the company pursues a hybrid business model of drug discovery and commercialization of its state-of-the-art technology platform.
Technology
Market
—— The growth of life-threatening, antibiotic-resistant pathogens highlights the urgent need for a new classes of antibiotics. —— Procomcure has promising lead-compounds of a new class of antibacterial agents with activity against methicillin-resistant Staphylococcus aureus (MRSA), and the company has proprietary tools for analysis of anti-bacterial modes of action. These tools originate from Procomcure’s patentable technology platform on protein-protein interactions, including a MRSA/MSSA strain collection composed of >3000 strains each manipulated for a single S. aureus gene in a constitutive or inducible fashion, which allows Mode of Action in a systematic and genome-wide manner.
—— While the global antibiotics market generated $ 42bn in 2009, representing 46% of anti-infective agent sales and 5% of the global pharmaceutical market, the smaller market of severe (nosocomial) infections caused by drug-resistant organisms is more tangible, offers higher drug prices and higher growth, and is therefore attractive. The global market of broad-spectrum antibiotics showed annual growth rates of 3.4–5% between 2005 and 2009. Our focus, the methicillin-resistant Staphylococcus aureus (MRSA) market, stood at $ 1.45bn in 2006, which then grew at a compound annual growth rate of 12.9% to reach $ 2.66bn in 2011. The forecasts are that the market will grow to reach $ 3.47bn by 2019.
66
Products Products
Indication
Stage of development
—— PCC293
MRSA
Preclinical
—— PCC560
MRSA
Preclinical
Procomcure technology
Company Profile Founded: 2007 Legal Form: GmbH Employees: 4 Management Team CEO: Kamil Önder CSO: Kamil Önder Public Funding aws PreSeed: € 100,000 aws Seed: € 1M Others (Tech2B, EU, FFG): € 500,000
Procomcure Biotech GmbH Magnesitstrasse 1 3500 Krems, Lower Austria, Austria +43 664 161 077 2 oender@procomcure.com www.procomcure.com
Biotech / Pharma – 67
ProFem
Products
is a company that develops new medicines for gynecological diseases. The aim is to address hitherto unmet medical needs in neglected therapeutic areas with high market potential. The present focus of interest is related to a disease pattern associated with biofilm growth, which up to now represents an unsolved medical problem in several extremely relevant indications. The lead product is the antifungal medicine Prof-001, which is now in clinical phase I.
Technology
Market
—— 5% of all women suffer from recurrent vulvovaginal infections caused by candida yeasts (RVVC), which up to now cannot successfully be treated. —— Making use of a specific drug repurposing approach, Profem addresses for the first time adhesion molecules, which play a crucial role in infection as targets for the treatment of infectious diseases. Preliminary tests in humans were extremely successful. —— A first patent covering the general therapeutic principle has been filed and has been granted in the USA recently. Follow-up patents covering drug formulation and other drug combinations are in preparation.
—— The new possibility to treat RVVC is relevant for about 200 to 300 million women worldwide. In figures, this means a market potential of more than $ 1bn. —— The global antifungal market is worth more than $ 11bn. —— The estimated market share of vaginal fungal infections is $ 2.5–3bn. —— Related diseases like chronic bacterial infections and chronic/recurrent infections of the lower urinary tract also affect more than 10% of all women worldwide.
68
Products
Indication
Stage of development
—— Candiplus (Prof-001)
(Recurrent) vulvovaginal candidiasis
Phase I
—— Candiplus oral (Prof-002)
Oropharyngeal candidiasis
Related to development of Candiplus
—— Prof-003
Urinary urge incontinence
Preclinical
Company Profile Founded: 2012 Legal Form: GmbH Employees: 1.5
Marion Noe, CEO of Profem
Management Team CEO: Marion Noe Advisor: Christian Noe Advisor: Peter Swetly Public Funding aws PreSeed: € 195,000 Others (ZIT, Inits): € 202,000 Private Funding
Profem GmbH Riglergasse 4/I 1180 Vienna, Austria +43 676 7203070 office@frau-und-gesundheit.at www.profem.at
€ 500,000
Biotech / Pharma – 69
RECARDIO
Products
is an Austrian-based life sciences company founded in 2011. Its focus is on regenerative therapeutic modalities for the treatment of cardiovascular diseases. After establishing proof-of-principle in vivo, it is developing multiple therapeutic leads and is entering the clinical development as the future regenerative medication for patients with various cardiovascular diseases, with the potential of improving their cardiac function, quality of life, and likelihood of survival.
Technology
Market
—— RECARDIO’s first non-invasive and innovative therapeutic concept is the combination of G-CSF with the recently available DPPIV inhibitors, leading to a significantly increased regenerative effect in the diseased cardiac tissue. Targeting two established modes of action ameliorates the effects of cardiac remodeling with the intended long-term benefit of reducing morbidity and increasing survival. —— Additional key issues: safe and easy administration, preclinical development completed, key patents issued.
—— Cardiovascular diseases are the number one cause of death in Western countries, claiming approximately 1.1 million lives in the US. Myocardial infarction (MI) causes the majority of cardiovascular deaths with an incidence of 600 per 100,000. Improvements in heart function with existing therapy methods are rather modest. Congestive heart failure (CHF), which develops after infarction, remains a major cause of morbidity and death and affects 4.8 million individuals in the US, with 400,000 new cases each year. Up to 74% of MI lead to CHF, which has a 5-year mortality of more than 60% in the affected population and an average survival rate of less than 1.7 years after diagnosis.
70
Products
Indication
Stage of development
—— REC 001
AMI
Phase IIb
—— REC 002
CHF
Preclinical
—— REC 003
PAD
Preclinical
Company Profile Founded: 2011 Legal Form: GmbH Employees: 3
Recardio technology
Management Team CEO: Roman Schenk CSO: Thomas Schöndorf CBD: Harald Kattnig Public Funding aws Seed: € 1M FFG: € 250,000 Private Funding
RECARDIO GmbH Lakeside B07b 9020 Klagenfurt, Carinthia, Austria +43 463 210 131 info@recardio.eu www.recardio.eu
€ 500,000
Biotech / Pharma – 71
roombiotic
Services
is a biotechnological company developing decontamination technologies based on airborne antimicrobial substances. These small molecules belong to secondary metabolites, which are involved in the signal transduction of microorganisms. The company specializes in the identification of novel antimicrobial substances from natural occurring microbial antagonists. The main focus is a residue-free decontamination of complex surfaces and microstructures with biogenic substances.
Technology
Market
—— Identification and synthesis of new volatile organic compounds from plantderived beneficial microorganisms —— The pipeline includes several small molecules that allow for a residue-free decontamination of hard-to-reach areas. —— The process of the microbiological stabilization also includes promoting the growth of beneficial microbes, which outcompete pathogens.
—— The primary cause of food loss is due to food spoilage after distribution (FAO). In the United States alone, this represents an economic loss of $ 1bn per annum. —— Markets targeted by roombiotic are food production (bakeries, dairy, meat processing). —— Additional markets are pharmaceutical industries and medical facilities.
72
Products
Description of Service
—— Analysis
Analysis of the present microbiome and identification of critical areas and microbiological contaminations
—— Development
Development of biological strategies to control and reduce contamination for specific production processes
—— Implementation
Implementation of a contamination control system based on effective organic agents to improve product quality and shelf life
Volatile antimicrobials enable the decontamination of microstructures (gray), which form shielding niches for microbes (green)
Company Profile To be founded: 2014 Legal Form: TBD Employees: 3 Management Team CRO: Stefan Liebminger (founder) CRO: Josef Ortner (Business Mentor) CRO: Gabriele Berg (Scientific Mentor) Public Funding aws PreSeed: € 200,000 Science Park Graz: € 26,000
roombiotic Petersgasse 12/1 8010 Graz, Styria, Austria +43 316 873 881 4 stefan.liebminger@tugraz.at http://sciencepark.at/unsere-firmen/448/roombiotic
Biotech / Pharma – 73
Savira is dedicated to the development of next-generation anti-influenza therapeutics. Savira employs rational, structure-based design of small-molecule drugs targeting the influenza virus polymerase based on the inhibition of two distinct protein domains. In May 2012, Savira signed a collaboration and license agreement with Roche for its complete polymerase inhibitor program. Technology
Market
—— Through a unique mechanism called ‘cap-snatching,’ the influenza virus forces the infected cell to produce viral proteins, eventually forming new infectious viral particles. Research by the EMBL identified the molecular architecture of both domains of the influenza polymerase crucial for this mechanism, the cap-binding domain and the endonuclease-active site. —— Structure-based medicinal chemistry programs have provided highly selective ligands, with binding affinities being increased by several orders of magnitude and improved in vitro inhibition of influenza virus replication in infected cells. —— In vivo antiviral proof of concept in mice with lethal influenza virus infection was demonstrated for both, cap-binding and endonuclease inhibitors. —— The most promising scaffold families have been protected worldwide by patent applications. Preclinical development is expected to start in 2014.
—— Influenza is an infectious viral respiratory disease and a major public health concern. Vaccines are considered to be an efficient prophylactic measure, but only a small part of the population is being vaccinated, and the production of vaccines against new subtypes may take several months. Thus, antivirals are an indispensible treatment option. —— The influenza therapeutic market is expected to grow steadily from $ 4bn in 2009 to over $ 10bn in 2019, overtaking vaccines. Currently, it is made up of two main groups, with neuraminidase inhibitors (Tamiflu, Relenza, Rapiacta, Inavir) dominating over M2-ion channel inhibitors. —— Development of viral resistance is a recurring concern—most recently with the global emergence of Tamiflu-resistant strains in the 2007/2008 season. As a consequence, there is significant potential in the market for novel, efficacious, and selective therapeutics less prone to the development of viral resistance.
74
Products —— Savira’s polymerase inhibitors are ideally placed to tap this market opportunity: binding to defined sites within the viral polymerase allows direct inhibition of viral RNA genome transcription; the structurally highly conserved sites are less prone to resistance development as they interact with host proteins, and minor structural changes have been shown to render the virus less virulent.
Company Profile
—— The collaboration and license agreement with Roche provides Savira upfront payments, R&D support, and milestone payments up to € 240M as well as royalties. Savira’s compounds will have the best possible access to the market through Roche’s very strong foothold in the field.
Savira Management: Oliver Szolar, Andreas Hauer and Helmut H. Buschmann
Founded: 2009 Legal Form: GmbH Employees: 12 Management Team CEO: Oliver Szolar CSO: Helmut Buschmann CFO: Andreas Hauer Public Funding aws Seed: € 1M Others (FFG, ZIT): € > 1M EU-FP7– FLUPHARM development partners: € 4M Private Funding
Savira pharmaceuticals GmbH Veterinärplatz 1, Building IA 1210 Vienna, Austria +43 1 25077 5904 office@savira.at www.savira.at
€ > 2.9M
Biotech / Pharma – 75
SeaLife Pharma
Products
is an innovative marine biotechnology company dedicated to the discovery and development of novel bioactive compounds. SeaLife Pharma’s R&D is focused on developing new and commercially valuable products derived from marine microbiology. By combining a robust screening process with purification chemistry and compound elucidation, the company is well positioned to rapidly discover new pharmaceuticals and natural products for consumer health care.
Technology
Market
—— The core aim of the company is the discovery of anti-infective compounds targeting bacterial, fungal, and viral infections with a focus on finding new antibiotics to treat Gram-positive infections such as MRSA and VRE. —— In addition to the therapy, the interruption of the transmission of bacteria, fungi, and virus has become a focus in SeaLife development, leading in an anti-infective polymer program. —— At the moment the company has 2 patents accepted, 1 in submission, and 2 others filed.
—— Global market for MRSA is forecast to increase from $ 1.6bn in 2008 to $ 2.6bn in 2014.
76
Products
Indication
Stage of development
—— SLP0904
Antibacterial compound MRSA–Skin Infection
Preclinical
—— SLP0905
Antibacterial compound Endocarditis
Preclinical
—— SLP0901
Disinfection
Pre-registration phase
Company Profile Founded: 2008 Legal Form: GmbH Employees: 16
Christoph Wiesner and Alexander Pretsch
Management Team CEO: Alexander Pretsch CSO: Christoph Wiesner CFO: Andreas Krems Public Funding aws PreSeed: € 100,000 Others: € 2.3M Private Funding
SeaLife Pharma Technopark 1 / Geb. B / EG 3430 Tulln, Lower Austria, Austria +43 2 272 626 06 office@sealifepharma.com www.sealifepharma.com
€ 2M
Biotech / Pharma – 77
S-TARget therapeutics is a biotech company founded in August 2010. It develops novel therapeutic vaccines to cure and prevent severe, life-threatening diseases that currently cannot be cured – including severe forms of allergy. The vaccines are based on a unique, proprietary technology platform that is capable of boosting patient’s immune system to cure various diseases in allergy and oncology. The lead candidate product, SG-100, is targeted against severe house dust-mite-derived allergies.
Technology
Market
—— House dust mites represent the world’s number one allergen, which leads to extremely severe forms of allergies. —— Unlike other drugs, S-TARget vaccines address the cause of the disease and not only the symptoms. —— The S-TARget technology platform is based on a 2-module system: a generic module (warhead) and a variable, disease-specific module (immunogen). —— The entire S-TIR platform is protected by a patent family. —— Proof of concept of the platform technology in allergy as well as oncology was successfully demonstrated in vitro as well as in vivo.
—— Allergies affect up to 30% of the Western population. —— The allergy treatment market currently shows revenues of about $ 3bn/year with a significant increase each year. —— Even the existing blockbuster allergy drug achieved a market share of only 2%, which shows the high unmet need for an appropriate treatment. —— In Europe, US, and Japan there are approx. 14 million patients diagnosed with severe allergic asthma derived from house dust mites, for whom currently there is no cure available.
78
Products Products
Indication
Stage of development
—— SG-100
Allergy
Preclinical
—— SG-200
Oncology
Preclinical
S-Target Management: Geert Mudde and Christof Langer Company Profile Founded: 2010 Legal Form: GmbH Employees: 3 Management Team CEO: Christof Langer CSO: Geert C. Mudde BD: Theodor Langer Public Funding aws PreSeed: € 160,000 aws Seed: € 1M FFG: € 0.3M
S-TARget therapeutics GmbH Mooslackengasse 17 1190 Vienna, Austria +43 664 516 003 2 office@s-target.com www.s-target.com
Biotech / Pharma – 79
TAmiRNA
Market
Products & Services
is a Research & Development company (in incorporation) that develops novel tools for the diagnosis and treatment of age-associated diseases. To achieve these goals, TAmiRNA capitalizes on a strong background in microRNA (miRNA) research – tiny non-coding RNAs with important roles for tissue regeneration and body homeostasis – and focuses on translating this knowledge into effective tools for the personalized diagnosis and treatment of age-related bone and cardiovascular diseases.
—— The global therapeutic Osteoporosis market will reach $ 11.4bn in 2015. —— Customers – Industry: Global trade partners, companies in the field of health care and prevention. —— Customers – Clients: Companies and persons active in age-related health care and prevention, assessment and treatment of Osteoporosis and Osteopenia; Patients suffering from bone and cardiovascular diseases.
—— TAmiRNA molecular Diagnostic Test for Osteoporosis Risk Assessment. —— Best-in-class research on miRNAs with focus on age-related bone and cardiovascular diseases.
Technology —— Automated gene expression analysis from cells, tissues, and biofluids; pharmacogenomics; stem cells and in-vitro models for functional microRNA analysis; preclinical model systems for drug research and development; IP on microRNA-31 as diagnostic and therapeutic target for osteoporosis (see figure). —— Indication: Osteoporosis is among the most severe age-related diseases in the 21st century. Thus, there is a great need for highly reliable and validated prognostic and predictive test systems for risk assessment and for the development of individual therapy. 80
—— Vision of TAmiRNA: Effective personalized treatment of age-related bone and cardiovascular diseases using miRNA applications. —— Technology: Conducting studies to screen miRNAs in blood samples from well-characterized clinical cohorts; Development of a non-invasive screening method for blood-circulating miRNAs; Development of diagnostic kits for reliable prognosis of progress and risk of the disease; Drug development using microRNAs for therapy and treatment of age-related diseases.
Company Profile
TAmiRNA technology
Founded: 2013 Legal Form: GmbH Employees: 2 Management Team CEO, co-founder: Otto Kanzler COO, co-founder: Matthias Hackl Co-Founder, Scientific Advisor: Johannes Grillari Co-Founder, Scientific Advisor: Regina Grillari Public Funding aws PreSeed: € 200,000 Private Funding
Tamirna GmbH Muthgasse 11 1190 Vienna, Austria +43 650 499 147 2 (scientific issues) +43 664 422786 1 (business issues) office@tamirna.com www.tamirna.com
Not disclosed
Biotech / Pharma – 81
Themis Bioscience is a biotechnology company developing vaccines to prevent infectious diseases. The company´s development focus is primarily on emerging and specialist indications, advancing promising vaccines from preclinical to late-stage clinical development phases. The company is using its core lead technology, Themaxyn, to create novel vaccines. The product portfolio includes vaccines against dengue, chikungunya, and other viruses.
Technology
Products Products
Indication
Stage of development
—— A
Dengue fever
End preclinical phase – Start phase I
—— B
Chikungunya fever
Phase I studies in 2013
Market Themis offices and laboratories
—— Themis’ core lead technology, ThemaxynTM, is a novel vaccine platform based on an approved and well-known measles virus vaccine and developed by the world-leading Institut Pasteur. —— ThemaxynTM is used to stably present transgenes at the virus surface directly to macrophages and dendritic cells without causing immune responses against the vector itself. —— First vaccine targets are emerging tropical and travelers’ diseases, including vaccines against dengue, chikungunya, and other viruses. —— The ThemaxynTM technology can easily be expanded to further indications. 82
—— Global market for vaccines was $ 14bn in 2010, with an annual growth rate of 13%. —— Market for novel and improved vaccines has grown at an annual rate of 38%. —— Importantly, it has been demonstrated that immunization with a ThemaxynTM chikungunya virus construct confers 100% protection in a relevant animal model. —— Chikungunya vaccine has completed preclinical testing and will start phase I studies in 2013. —— Dengue vaccine has successfully undergone non-human primates experiments and is about to enter clinical phase I in early 2014.
Company Profile Founded: 2009 Legal Form: GmbH Employees: 5 Management Team CEO: Erich Tauber Public Funding + Private aws, FFG, Inits, Founders, Omnes Capital, Ventech: € 8.5M
Themis Bioscience GmbH Muthgasse 11/2 1190 Vienna, Austria +43 1 236 71 51 office@themisbio.com www.themisbio.com
Biotech / Pharma – 83
The Siesta Group is a comprehensive service provider supporting the measurement of sleep, wakefulness, and brain activity in clinical trials and research. This encompasses, among other things, high-quality services concerning polysomnography (PSG), pharmaco-electroencephalography (pharmaco-EEG) and event-related potentials (ERP). Services range from consultation, site selection, site training, centralized data scoring and analysis, data quality control, to device rentals.
Technology —— The Siesta Group provides a technological platform for measuring brain activity, sleep, and vigilance in clinical trials and research. State-of-the-art as well as innovative signal processing software is at the core of this platform. —— The company has developed the Somnolyzer 24x7® system, the world’s most efficient automated analysis system for sleep profiles based on polysomnography (biosignals measured in the sleep lab). For the diagnostic market, the software is now owned and marketed 84
Market
Services
—— The Siesta Group primarily targets the worldwide pharmaceutical research market for CNS-active drugs, especially in early phase (I and II) as well as preclinical. —— Additional markets are academic research and medical device industry
—— Central data scoring, analysis, and delivery —— Equipment leasing —— Site identification, feasibility, site training, harmonization —— Protocol consulting —— Advanced analysis, biomarker research
Company Profile
by Philips Respironics. The Siesta Group employs Somnolyzer in clinical trials for utmost reliability in sleep measurement. —— The processes surrounding Somnolyzer 24x7 and the company’s EEG analysis tools, including secure and efficient internet-based transmission of data from the investigator site to the scoring center, serve as immediate data quality control and help ensure an efficient harmonization of measurement within and across sites.
Founded: 2002 Legal Form: GmbH Employees: 10
The Siesta Group Service
Management Team CEO: Georg Dorffner CSO: Peter Anderer CFO: Peter Runa Public Funding aws Seed (2003): € 500,000 aws TFP guarantees (2004): € 600,000 EU project SENSATION (grants): € 215,500 FFG (grants and loans in total): € 490,000 Private Funding
The Siesta Group Schlafanalyse GmbH Schlosshofer Strasse 11, 3rd floor 1210 Vienna, Austria +43 1 955 12 13 info@thesiestagroup.com www.thesiestagroup.com
€ 1.9M
Biotech / Pharma – 85
Tissue Med Biosciences is a biotech company developing novel therapies for chronic diseases. Therapeutic developments (human recombinant proteins) from TMB target indications in the field of diabetic foot ulcer, hematology, and musculoskeletal diseases.
Technology
Market
—— Tissue Med Biosciences’ (TMB) lead development targets the indication of diabetic foot ulcer (DFU), a serious consequence of type 2 diabetes. —— The multifunctional recombinant protein TMBP-3 has significant competitive advantages as it targets the three relevant factors for healing diabetic foot ulcers: wound closure, growth of new vessels, and activation of the immune system. —— The preclinical safety program was completed in 2013 and shows excellent tolerability in long-term toxicological studies. —— A clinical phase 1 study will be initiated in late 2013. —— TMBP-3 is formulated in hydrogel for topical application.
—— The market of chronic diseases is constantly growing, resulting from obesity and diabetes: more than 20 million diabetic foot ulcer patients worldwide are waiting for a satisfactorily effective and easy-to-administer therapy (15% of all patients with type 2 diabetes develop a diabetic foot ulcer). —— Treatment of decubitus ulcers would be applicable worldwide to 9 million patients, while 8 million patients worldwide suffer from chronic venous ulcers and could be treated with TMBP-3. —— Pipeline developments target large and growing markets of a similar size (OECD 2011, The Lancet 2011).
86
Products Products
Indication
Stage of development
—— TMBP-3
Diabetic foot ulcer
Preclinical
—— TMBP-4
Hematology
Under development
—— TMBP-5
Musculoskeletal diseases
Under development
Company Profile
Tissue Med Biosciences Research
Founded: 2004 Legal Form: GmbH Employees: 8 Management Team CEO, Founder: Rudolf Berger CSO: Maximilian Berger Public Funding aws Seed: € 450,000 aws Double Equity: € 685,000 Others (FFG, Lower Austria): € 1.24M Private Funding
Tissue Med Biosciences Magnesitstrasse 1 3500 Krems, Lower Austria, Austria +43 2732 87470 - 310 office@tmbiosciences.com www.tmbiosciences.com
Not disclosed
Biotech / Pharma – 87
TUBE Pharmaceuticals is a biotech company with a focus on small molecules derived from natural products for targeting approaches for safer and more efficacious therapies. The company is developing a pipeline of various products by using different targeting principles for conjugation to its toxin platforms, addressing major disease areas with unmet medical needs. The toxin platforms of proprietary Tubulysins (Cytolysins) and Epothilones are available for licensing.
Technology
Market
—— The toxin platforms of proprietary Tubulysins (Cytolysins) and Epothilones are proven pay-loads for a variety of targeting approaches used by TUBE itself and by its licensees. —— TUBE’s own development product is a nanopharmaceutical using a tubulysin as its active principle, which shows an excellent efficacy and safety profile in many in-vivo studies. —— TUBE has licenses for natural tubulysins/cytolysins and epothilones and holds its own IP on these compound classes.
—— The market volume for conjugation products is in the multibillion euro range. The key indication areas are especially oncology and hematology. —— TUBE also offers synthesis services for complex organic molecules, e.g. toxic payloads, linkers, building blocks.
88
Products Products
Indication
Stage of development
—— Poly-CD-PEG-Tub
Oncology / Hematology
Preclinical
—— Cytopep
Oncology
Preclinical
Company Profile Founded: 2011 Legal Form: GmbH Employees: 3 Management Team CEO: Wolfgang Richter CBO: Michael Ahrweiler Public Funding aws Seed: Not disclosed Private Funding
TUBE Pharmaceuticals GmbH Leberstr. 20 1110 Vienna, Austria +43 1 740 935 100 info@tubepharma.at www.tubepharma.at
Not disclosed
Biotech / Pharma – 89
ugichem
Products
Based on the innovative Ugimer® platform, ugichem is developing innovative antisense therapeutics with a unique therapeutic efficacy profile for immune-mediated inflammatory diseases (IMID), where existing therapies are insufficient or do not work. ugichem primarily focuses on rheumatoid arthritis (RA) as lead indication.
Technology
Market
—— Antisense drugs are assessed to become the next major breakthrough in molecular medicine. The first product has entered the market and numerous new antisense drugs are currently in clinical development. However, the standard, RNA-based, antisense concepts have failed so far in the IMID field. The reasons are insufficient activity in immune-system-relevant organs and cells in combination with unspecific immune system stimulation. —— Ugimers are non-RNA-based antisense drugs with a unique combination of delivery, efficacy, and safety parameters confirmed to provide a new and more specific therapeutic efficacy profile for immune-mediated inflammatory diseases with high medical need. —— Ugimers are protected by a broad patent portfolio, exclusively owned by ugichem.
—— The global rheumatoid arthritis market was $ 18.6bn in 2012 and is expected to grow from to $ 26bn in 2017.
90
Products
Indication
Stage of development
—— Ugi-RA
Rheumatoid arthritis
Preclinical
—— Ugi-IMID
Immune-mediated inflammatory diseases
Preclinical
Company Profile
ugichem offices and laboratories
Founded: 2003 Legal Form: GmbH Employees: 9 Management Team CEO: Holger Bock CSO: Thomas Lindhorst CTO: Jürgen Soutschek Public Funding aws Seed: € 1M FFG: € 1.9M Private Funding
ugichem GmbH Mitterweg 24 6020 Innsbruck, Tyrol, Austria +43 512 282 285 10 contact@ugichem.at www.ugichem.com
€ 6.75M
Biotech / Pharma – 91
Valericon
Products
develops novel drugs to improve patient outcomes in the therapeutic areas of anxiety and epilepsy. Valericon’s strength is the proprietary screening technology enabling rapid identification of drug candidates from plant extracts or chemical libraries. We develop a novel class of specific GABA A receptor modulators based on a natural compound isolated from valerian roots as potential anxiolytics and anticonvulsants.
Technology
Market
—— Subunit-specific modulators of GABA A receptors are expected to exhibit a more selective therapeutic profile with fewer side effects than the widely used benzodiazepines. —— Valerenic acid from Valerian root extracts is a natural product that causes anxiolysis without sedation. It binds with nanomolar affinity and interacts selectively with GABA A receptors comprising 3 subunits. —— Neurons expressing GABA A( 3) receptors are the molecular target for novel anxiolytics that do not cause sedation. —— VAD1 and VAD2 are small molecules interacting specifically with GABA A receptors comprising 3 subunits. VAD1 and VAD2 cause anxiolysis without sedation. This mechanism was proven in vivo in a mutant mouse model. —— Valericon has applied for patents on several subunit-selective GABA A receptor modulators.
—— There is an unmet demand for novel drugs to treat anxiety, one of Valericon’s major therapeutic targets. The global anxiety disorders market is predicted to grow to $ 5.1bn in 2017 in the US and the five major European markets. —— Valericon will focus on the European and US Markets. —— Valericon’s business model stands on three pillars, all of them make use of the core screening competence: 1. Development of valerenic acid and derivatives as a class of novel-specific modulator of GABA A receptors 2. Collaborative drug screening program (service for fee) 3. HERG screening (service for fee)
92
Products
Indication
Stage of development
—— VAD1
Anxiety, epilepsy
Preclinical
—— VAD2
Anxiety, epilepsy
Preclinical
Valericon technology
Company Profile Founded: 2011 Legal Form: GmbH Employees: 2 Management Team CEO: Steffen Hering Public Funding
Valericon GmbH Leidesdorfgasse 14/TOP 6 1190 Vienna, Austria +43 664 820 074 2 office@valericon.com www.valericon.com
aws PreSeed: € 91,637
Biotech / Pharma – 93
Valneva
Products
is an European biotech company dedicated to vaccine development and antibody discovery for the treatment of infectious diseases. It was created in 2013 through the merger between Intercell AG and Vivalis SA. Valneva generates diversified revenue from both its marketed product, a vaccine for the prevention of Japanese encephalitis (IXIARO®), and licensed technology platforms. It has more than 35 research and commercial agreements with the world’s largest pharmaceutical companies.
Technology
Market
—— IXIARO® / JESPECT® Japanese Encephalitis Vaccine
—— Vaccine for travelers to endemic regions; also distributed to US military. Longterm potential of in-market sales of ~€ 200M. Partners: Novartis, CSL, Biological E. —— Partnered with several companies. First veterinary vaccine approved in 2012; NDA filed for first human vaccine in 2013 (Partner Kaketsuken). —— A collaborative & commercial agreement with Sanofi Pasteur on several infectious targets: up to € 200M milestones/ royalties. —— Adjuvant can be used to improve vaccines in different indications. The most advanced studies are in TB.
—— EB66® Vaccine Production Platform derived from duck embryonic stem cells
—— VIVA|Screen™ Antibody Discovery Platform for fully human therapeutic mAbs
—— IC31® Adjuvant for Vaccines
94
Products
Indication
Stage of development
—— IXIARO® / JESPECT® / JEEV®
Japanese Encephalitis
Marketed
—— EB66® Vet. Vaccines
e.g.: Egg Drop Syndrome
Approved vet. vaccine on EB66® (w/ Kaketsuken)
—— EB66® Human Vaccines
e.g.: H5N1 Pandemic Influenza
Regulatory approval (JP, w/ Kaketsuken) / Phase II (US, w/ GSK)
—— IC43 Vaccine Candidate
Pseudomonas aeruginosa
Phase II/III (co-funding by Novartis)
—— IC31® Partnered Programs
e.g.: Tuberculosis
3 TB candidates in Phase II and Phase I (w/ SSI, Sanofi)
—— IC84 Vaccine Candidate
Clostridium difficile
Phase I in house, Novartis option
—— IC15 Vaccine Candidate
Lyme Disease
Preclinical
Company Profile Founded: 2013 (1997 Intercell AG) Legal Form: GmbH (Valneva Austria GmbH is a subsidiary of Valneva SE) Employees: ~140 Management Team
Valneva research
CEO: Thomas Lingelbach CBO: Franck Grimaud CFO: Reinhard Kandera CSO: Majid Mehtali Public Funding (Intercell AG 1997-2012) aws Seed: € 725,000 erp/ FFF/ FFG/ ZIT: € 27,570,000 Private Funding
Valneva Austria GmbH Campus Vienna Biocenter 3 1030 Vienna, Austria +43 1 206 20 info@valneva.com www.valneva.com
€ 484,000,000
Biotech / Pharma – 95
Vela Laboratories
Product & Services
is a GMP-certified contract laboratory offering protein characterization services to the pharma and biotech industries. The company focuses on the analysis of biopharmaceuticals, biologics, and biosimilars at all stages of product development, from preclinics up to market approval.
Technology
Market
—— Vela is a partner for process development during early phases (preclinical development, GLP), during clinical development (GCP/GMP), and up until product release and submission (GMP, method validation, stability studies, batch release). —— Vela is a partner for preclinical and clinical development and consulting (study analytics and organization…) with emphasis on pharmacology, pharmacokinetics, pharmacodynamics, and immunogenicity testing (ADA´s), as well as bioequivalence and ADME studies.
—— Support for market authorization application of biosimilars: —— In 2012, more than 15 different proteins (mAbs, rhu-proteins, peptides) were in the development pipeline. —— Clients: 18 (Austria, Europe, USA/ Canada, India) —— Vela’s sales are growing rapidly and consistently: 2007: € 300,000 2008: € 600,000 2009: € 900,000 2010: € 1,900,000 2011: € 2,200,000 2012: € 2,700,000
96
—— Physico-chemical analysis —— Immunological and immunochemical methods —— Bioassays: potency, efficacy, stability —— Pharmaceutical technical procedures and Pharm. EU methods for API, DS, DP —— Analytical support for preclinical and clinical trails (PK, PD, bioequivalence studies)
—— Method validation according to ICH guidelines —— Storage and logistics under GMP conditions —— Stability studies, accelerated studies, L&E studies —— Batch release in the EU by a qualified person
Vela Management: Andreas Nechansky, Markus Fido, Armin Franz Company Profile Founded: 2006 Legal Form: GmbH Employees: 28 Management Team CEO: Markus Fido COO: Andreas Nechansky CFO: Armin Franz Public Funding aws Seed: € 275,000 ZIT/LISA: € 670,000 Private Funding
Vela pharmazeutische Entwicklung und Laboranalytik GmbH Brunner Straße 69/3 1230 Vienna, Austria +43 1 890 597 911 office@vela-labs.at www.vela-labs.at
€ 1.5M
Biotech / Pharma – 97
ViraTherapeutics
Products
develops highly potent anti-cancer therapeutics based on oncolytic (cancer-destroying) viruses. Our proprietary oncolytic virus, “VSV-GP,” efficiently destroys cancer cells, while leaving normal tissues unharmed. ViraTherapeutics’ team is currently performing preclinical safety and efficacy studies for VSV-GP and aims to conduct initial clinical trials in cancer patients in three years.
Technology
Market
—— Oncolytic viruses (OV), which preferentially replicate in cancer cells and thereby destroy cancer tissue, are a highly promising novel class of anticancer biopharmaceuticals. —— ViraT’s OV VSV-GP has been shown to be highly effective in, or even cure (!), all cancers tested so far in mouse models. —— VSV-GP is the first OV that does not induce neutralizing antibodies to the virus itself and therefore allows repeated systemic application without loss of efficacy. —— Thus, VSV-GP therapeutics have the potential to revolutionize cancer therapy. —— ViraTherapeutics holds patents and patent applications to protect the unique VSV-GP technology in all the major pharmaceutical markets.
—— The global market for cancer drugs was € 41bn in 2010 and is estimated to be around € 60bn by 2016. —— As conventional treatment regimens reach their limits, there is an urgent need for new effective cancer therapeutics. —— The first two target cancers addressed by ViraT will be melanoma and brain cancer. The melanoma market in the seven major pharmaceutical countries is estimated to grow with a compound annual growth rate of ca. 9% from € 1bn in 2012 to about € 2bn in 2021. There is also a strong potential opportunity for new drugs to enter the market for brain tumors; a market which is expected to reach € 1bn in 2016 in the seven major pharmaceutical markets.
98
Products
Indication
Stage of development
—— VSV-GP
Melanoma
Preclinical
—— VSV-GP
Glioblastoma
Preclinical
ViraT Team: Ludwig Weiss and Dorothee von Laer (center)
Company Profile Founded: 2013 Legal Form: GmbH Employees: 4 Management Team CEO: Ludwig Weiss (co-founder) CSO: Dorothee von Laer (co-founder) Public Funding aws PreSeed: € 182,000 CAST: € 18,000
ViraTherapeutics GmbH Peter-Mayr-Str. 4b 6020 Innsbruck, Tyrol, Austria +43 699 190 855 27 office@viratherapeutics.com www.viratherapeutics.com
Biotech / Pharma – 99
Xiber Science
Products
is improving Survival & Outcome of Critical Care & Transplant Patients. Up to 50% of critical care patients are affected by organ failure – 40% of them die; 37% of the survivors stay handicapped for life. 20-40% of transplant patients suffer from primary graft dysfunction (PGD). PGD is the leading cause of early death after transplantation. To date, no specific treatment to prevent organ failure is available. Xiber develops first-in-class peptide drugs that prevent organ damage/failure.
Technology
Market
—— The breakdown of endothelial and epithelial barriers is a major contributor to the pathogenesis of many inflammatory, infective, cardiovascular and cancerous diseases. —— Xiber has developed a high-content assay (HCA) to screen for substances that protect endothelia and epithelia from breakdown. —— Employing our HCA, we have identified synthetic peptides that prevent organ failure. —— Patents: 2011 PCT, 2012 national phases initiated in USA, CA, EU, CN, RU, and JP
—— Initially, Xiber will concentrate on indications (see below) with a market volume of $ 600M —— In the medium term, Xiber aims to develop a prophylactic treatment for critical care and transplant patients. —— To date, there is no approved drug on the market to prevent organ failure.
100
Products
Indication
Stage of development
—— Xib13-01
Acute lung injury
Preclinical
—— Xib13-02
Transplantation
Preclinical
—— Xib13-03
Severe burns
Preclinical
Xiber’s high-content assay Company Profile Founded: 2009 Legal Form: GmbH Employees: 2 Management Team CEO: Sonja Reingruber CSO: Peter Petzelbauer CFO: Michael Hoffmann Public Funding aws Seed: € 500,000 Others: € 200,000
Xiber Science Josefigasse 24 2353 Guntramsdorf, Lower Austria, Austria +43 699 170 540 86 s.reingruber@xiberscience.com www.xiberscience.com
Biotech / Pharma – 101
XworX
Services
– The App Store for Bioinformatics. High throughput technologies in life sciences, leading to rapid progress in personalized medicine and biotechnology, impose a great challenge in data handling and the extraction of the relevant biological and medical information. Responding to this demand, we provide an app store and a cloud-enabled software platform for community driven app development as well as the corresponding marketplace.
Technology / Innovation
Market
—— Dynamic Apps: XworX implements an extended app model that integrates all components like workflow, cloud-enabled services, data logging, and reporting within any single app, providing auto-deploying, easily portable, and ready-to-use compact software solutions. This makes it ideally suited for the specific requirements of life sciences applications: —— Auto-deployment, no configuration effort —— Full support of big data, security, data logging, and advanced data mining —— Access to tools and data anywhere: desktop, mobile, web client
—— The global bioinformatics market was $ 2.3bn in 2012, forecasted to reach $ 9.1bn in 2018, at a CAGR of 25.4% from 2012 to 2018. —— Bioinformatics platforms have the largest market share with nearly 50% of the market revenue. —— This segment is also the fastest-growing market with an estimated 54% of the total market growth from 2012 to 2018.
102
Services
Description of Service
—— Next Generation Software Platform & Apps
Our “dynamic apps concept” provides easily portable, ready-to-use solutions. Our comprehensive software environment simplifies the app development, enabling even non-IT experts (life sciences researchers, statisticians, bioinformaticians,…) to develop high-quality, commercial apps directly from their research tools and to share and commercialize them via our app store.
—— Next Generation Market Place
A marketplace for apps, app developers, and crowd-funding of app projects. It will facilitate community-driven app development, wiki documentation, and expert review.
CEO, Albert Kriegner
Company Profile Founded: 2014 Legal Form: GmbH Employees: 8 Management Team CEO: Albert Kriegner CTO: Visne Ilhami Public Funding
XworX Muthgasse 11 1190 Vienna, Austria +43 699 194 605 35 albert.kriegner@yahoo.com www.xworx.org
aws PreSeed: € 200,000
Biotech / Pharma – 103
Zytoprotec
Products
is a biotech company that specializes in “cell protection / cell repair” and was founded in February 2007. The company is currently focusing on cytoprotection with the first innovative product for renal therapies: PD-Protec. The lives of millions of people/patients worldwide can be saved or improved in the long run by these patent-protected research results. Additional products and research areas in the field of cytoprotection are already being planned.
Technology
Market
—— Most advanced product candidates focus on the treatment of patients suffering from kidney failure. For these patients, peritoneal dialysis (PD) is an established treatment option. —— PD improves quality of life and reduces costs incurred to the health care system in comparison to hemodialysis (HD). —— Zytoprotec’s preclinical research and the recently completed Phase I/II trial have demonstrated that the cytoprotective effects of PD-Protec™ promise to protect the peritoneum from damages caused by commercial PD-fluids. Patent: PD-Protec™ is based on PCT/ AT2008/000072 - WO 2008/106702 European patent was granted 23 October, 2012.
—— Overall, the size of the global dialysis market was approx. $ 75bn —— in 2011 with approx. $ 62bn attributable to the segment dialysis services and approx. $ 13bn to the segment dialysis products. —— Based on information available, companies operating in the global dialysis market have shown an average share price increase of 40% over the last 5 years, while spending only about 5% of revenues on R&D.
104
Products
Indication
Stage of development
—— PD-Protec™
Dialysate with a cytoprotective effect to reduce major complications of PD treatment
Phase I/II
—— Ico-Protec™
Cytoprotective glucose-free PD-fluid
Preclinical
—— OMNI-Protec™
up-regulating the cellular stress response in endothelial cells as novel treatments for diabetics that also suffer from hypertension
Preclinical
Company Profile Founded: 2007 Legal Form: GmbH Employees: 17
Zytoprotec research
Management Team CEO/CFO: Michael Hoffmann CSO: Christoph Aufricht Public Funding aws Seed: € 1.0M Others (FFG, ZIT): € 2.53M Private Funding
Zytoprotec GmbH Stadiongasse 2/13 1010 Vienna, Austria +43 1 40 620 02 office@zytoprotec.com www.zytoprotec.com
€ 6.0M
Biotech / Pharma – 105
Medtech Located in the heart of Europe, Austria has one of the world’s best healthcare systems. Along with high-class clinics, excellent research facilities and well-trained doctors, it is also based on superb equipment incorporating state-of-the-art technology. Not only does this make Austria an attractive market for medical technology products, it also makes it an important location for development and production which benefits from a long tradition in the field of engineering and precision mechanics. 106
107
4a medicom
Products
has developed a capillary microfluidics technology, which allows minimally invasive, safe, pain-free, fast, and easy testing of blood components. The system enables patients suffering from diabetes to quickly self-monitor their blood glucose levels. Contrary to the usual measuring methods employed today, which require the handling of several separate components, the 4a medicom product integrates lancing device, lancet, and test strip into one easily operated disposable product—the “GlucoPearl”— so measurement can be done in one single step: “Measuring at the push of a button.” Basically, the GlucoPearl product has been conceived as “PEARL” platform technology and can be used in the future for various target groups depending on the customer’s requirement.
Products
Application
Stage of development
—— GlucoPEARL
Blood Glucose Monitoring System
IVD II/B Preclinical
Market —— According to the WHO, the prevalence of diabetes will increase to 370M (4.5% of the global population) in 2030. The world market for blood glucose monitoring systems is estimated at $ 9bn (2012) with annual growth rates of ~7%. —— The greatest relative increases of diabetes will occur in the Middle Eastern, sub-Saharan Africa, and India.
—— For sales: A distinction must be made between two major target markets: (1) Point-of-Care Market (POC) – professional users in medical practices, hospitals, and nursing services, and (2) Self-Monitoring of blood-glucose market (SMBG) – patient’s own measurement. 4a medicom’s first target market will be the POC market with a subsequent launch in the SMBG market.
Technology Company Profile
—— GlucoPEARL combines lancing unit, lancet, and test strips all in a single device. “Measurement at the push of a button.” —— Easy-to-use, safe, pain-free, minimally invasive device analyzes quickly and delivers an all-in-one application for medical diagnostics as well as for sport medicine and wellness applications —— Integrated lancing, blood acquisition, and detection in a single disposable unit (one-step consolidated testing unit) 108
—— Thin-film capillary microfluidics technology uses nanoliter quantities of whole blood —— Screening via visual test strip —— Photometric analysis of glucose levels and subsequent monitoring via mobile phone are being developed —— GlucoPEARL and all planned product generations that build on its technology, have comprehensive patent protection.
4a medicom product
Founded: 2006 Legal Form: GmbH Employees: 25 Management Team CEO, founder: Reinhard Hafellner CFO: Sylvia Fauland CCO: Thomas Exel Public Funding aws: € 1M Others (FFG, SFG, EFRE): € 4.3M Private Funding
4a medicom GmbH Industriepark 1 8772 Traboch, Styria, Austria +43 384 2451 066 00 office@4a.co.at www.4a-medicom.at
€ 6.1M
Medtech – 109
AFreeze
Products
The CoolLoop® cryoablation catheter makes treatment of atrial fibrillation simple, safe and successful
Technology
Market
—— Treatment of atrial fibrillation by catheter ablation is a lengthy and complex procedure. —— AFreeze has developed a novel cryoablation system to treat atrial fibrillation. Instead of using heat, AFreeze uses cryoenergy to induce long circular lesions in the heart. The system is extremely simple to use (single-shot device) and safe. In addition, the loop form of the catheter enables new treatment modalities. —— The CoolLoop® system has successfully concluded a clinical study in two study centers in H1, 2013. —— AFreeze owns six distinct patent families.
—— The global market for electrophysiology is worth USD 2.4bn (2012). —— It shows double-digit growth rates, driven by an ageing population, an increased usage of catheter ablation, and an increasing number of specialized centers performing such procedures. —— More than 4.5M people are affected by atrial fibrillation (AF) in Europe. —— The number of AF patients in Germany has increased by 73% over the last 15 years.
110
Products
Application
Stage of development
—— CoolLoop®
Catheter ablation of atrial fibrillation
Phase III Approved / in Approval procedure
—— Tip-Catheter
Atrial fibrillation, other arrhythmia
Phase III / Under development
Company Profile Founded: 2008 Legal Form: GmbH Employees: 12
AFreeze technology
Management Team CEO: Gertraud Unterrainer CTO: Gerald Fischer CMO: Florian Hintringer Public Funding aws PreSeed + Seed: € 1.1M Others (FFG, CAST, EFRE, Standortagentur Tirol…): € 1.4M Private Funding
AFreeze GmbH Eduard Bodem Gasse 8 6020 Innsbruck, Tyrol, Austria +43 512 209 012 0 info@afreeze.com www.afreeze.com
€ 2M
Medtech – 111
Anagnostics
Products
provides diagnostic DNA and protein (e.g. antibody) test kits for complex diagnostic demands by offering an automated and integrated microarray technology (single device) for testing serum, plasma, urine, saliva, or liquor. Anagnostics focuses on integrated sepsis diagnostics by providing early multiplexed pathogen detection (4 h) from whole blood and therapeutical monitoring of a multitude of biomarkers.
Products
Application
Stage of development
—— Bacteria testing
Sepsis
IVD, marketed
—— Fungi testing
Sepsis
IVD, RUO
—— Antibiotic-resistance testing
Sepsis
IVD, under development
—— Monitoring inflammation
Sepsis
IVD, marketed
—— KRAS, BRAF testing
Companion diagnostics
IVD, marketed
—— EGFR testing
Companion diagnostics
IVD, RUO
Technology —— Hyborg system including device, software, and consumables for applications such as: highly paralleled DNA tests based on Anagnostics’ proprietary compact sequencing technology; highly paralleled immunotests based on Anagnostics’ proprietary compact profiling technology —— Clinical test for early pathogen detection from whole blood (sepsis): bacteria, fungi, and antibiotic resistances. —— Companion Diagnostics tests for mutations in the KRAS, BRAF, and EGFR gene —— DNA and protein microarray technology allows simultaneous analysis of several hundreds of DNA or protein markers in a minimal sample (e.g. 100µl plasma) —— Combination of real-time analysis and flexible sample processing (temperature, liquids) yields “high-content” data of a multitude of markers 112
—— Hyborg is the first fully automated allin-one device integrating a thermocycler, hybridization station, and fluorescence scanner for real-time (kinetic) DNA and protein microarray analysis —— Precise, fast, inexpensive, and simultaneous testing of DNA or protein markers in a sample is carried out in a cylindrical microarray called hybcell
Anagnostics technology Company Profile
Market
Founded: 2006 Legal Form: GmbH Employees: 11
—— $ 4bn in 2010 (Molecular Diagnostics) CAGR of 11% —— Addressing additional markets with protein-based tests (inflammation markers) —— Exponential growth of sales has been established
Management Team CEO: Christoph Reschreiter CSO: Bernhard Ronacher Public Funding aws PreSeed + Seed: € 600,000 Others: € 130,000 Private Funding
Anagnostics Bioanalysis GmbH Westbahnstrasse 55 4300 St. Valentin, Lower Austria, Austria +43 7435 58193-0 info@anagnostics.com www.anagnostics.com
€ 320,000
Medtech – 113
CVTec
Products
focuses on developing software tools for neurosurgery and neuroradiology, to enable physicians to concentrate on their core business and to improve life-saving operations. CoilControl3D is the first tool to automatically derive the only known success parameter of cerebral aneurysm operations instead of the actually subjectively biased estimations.
Technology
Market
—— Cerebral aneurysms are balloon-like malformations of brain arteries with the risk of rupture and life-threatening bleeding. To prevent the rupture, physicians fill out the aneurysm with microcoils. But the only known success parameter of this procedure is currently estimated by the attending physician. This leads to an overestimation by up to 30%, which results in very dangerous situations for patients. —— CoilControl3D is a software to calculate this parameter from automatically derived 3D reconstructions. Thus, we achieve a reduction in the complication rate as well as an improvement in the treatment quality. The patients as well as the physicians and cost bearers benefit from this tool. Further products like CoilAlarm (minimizing risk of stroke), FlowControl (blood flow analysis) and RiskControl (patient-specific rupture risk analysis) are in the development pipeline. —— Two patents are pending; further patents are in development.
—— In Europe there are about 72,000 microcoiling procedures per year. The use of the software will be charged as a service, with a total market volume of about € 86M per year in Europe. —— Due to the increasing availability of CT and MRI, the number of procedures and examinations is rising. Like in Japan, comprehensive scans will lead to an enormous rush demand on coiling operations and increase the necessity for patient-specific risk assessment. —— Insurance companies have estimated the annual socioeconomic costs of aneurysm rupture to be about € 1.9bn for Germany alone.
114
Products
Application
Stage of development
—— CoilControl 3D
Cerebral aneurysms
IIb, under development
—— CoilAlarm
Cerebral aneurysms
IIb, under development
—— FlowControl
Cerebral aneurysms
IIb, under development
—— RiskControl
Cerebral aneurysms
IIb, under development
Company Profile
CVTec Management team: Georg Mach, Thomas Ruhm, Camillo Sherif
Founded: in progress Legal Form: GmbH Employees: 4 Management Team CEO, CTO: Georg Mach CEO, CSO: Camillo Sherif CEO, CFO: Thomas Ruhm Public Funding aws PreSeed: € 165,000 INiTS: € 35,000 Private Funding
CVTec Cerebrovascular Technologies GmbH Mariahilfer Strasse 136/1.10 1150 Vienna, Austria +43 1 236 728 951 10 office@cvtec.at www.cvtec.at
€ 135,000
Medtech – 115
Dioptex
Products
is an innovative medical technology company located in Austria, the center of Europe. The company was founded by Albert Daxer as a research and development company in 2003. The focus is mainly on research and development in eye surgery and ophthalmology. The technology is a “spin-off” of Daxer´s scientific work at the Department of Ophthalmology, Medical University of Innsbruck, Austria. The innovative products of DIOPTEX are manufactured almost exclusively in Austria and distributed worldwide.
Technology
Market
—— The novel corneal intrastromal implantation surgery (CISIS) is a minimally invasive technology to correct short-sightedness (myopia) and keratoconus, a degenerative corneal disorder. —— CISIS allows treatment of the entire range of myopia and keratoconus including cases beyond 8 diopters, but without the need of intraocular surgery. —— Dioptex has developed a PocketMaker® microkeratome to generate a closed corneal pocket that allows the insertion of the MyoRing®. —— The MyoRing® is a permanent contact lens, which is squeezed into the cornea slightly underneath the cornea surface. The MyoRing® is developed and designed for the treatment of keratoconus and myopia up to almost 20 diopters.
—— World market for implantable contact lenses (CISIS) was estimated up to € 6bn in 2005 with a market potential of 1.5bn patients.
116
Products
Application
Stage of development
—— Pocketmaker
Corneal surgery
IIa, marketed
—— MyoRing
Keratoconus, myopia
IIb, marketed
Service —— CISIS technology training
Company Profile
Dioptex product
Founded: 2003 Legal Form: GmbH Employees: 3 Management Team CEO: Albert Daxer Sales + Marketing: Erwin Weglehner Public Funding aws Seed: € 500,000 Others: Not disclosed Private Funding
Dioptex GmbH Baumbachstraße 6 4020 Linz, Austria +43 732 774 876 office@dioptex.com www.dioptex.com
Not disclosed
Medtech – 117
DirectSens
Products
is dedicated to the development of carbohydrate biosensors that can be used for medtech and industrial applications. Based on over 10 years of extensive research, we developed a technology platform for 3rd generation biosensors. The great flexibility of our technology, combined with the simple architecture of the biosensors, allows us to precisely meet the requirements of our customers.
Technology
Market
—— Biosensors are analytical devices used for the detection of an analyte with the help of a highly sensitive biological component. —— DirectSens develops biosensors for single-point as well as continuous measurements of glucose in blood and of other sugars for various industrial applications. —— The patented core element of the DirectSens technology is the enzyme Cellobiose Dehydrogenase. —— By exploiting the natural function of the biocatalyst, DirectSens can realize a simple sensor architecture, omitting any additional elements necessary in conventional biosensors. —— This DirectSensing approach results in highly accurate sensor performance combined with simple manufacturing. —— Two patents filed.
—— Diabetes is a metabolic disorder causing dangerous blood glucose fluctuations, forcing patients to measure their blood glucose level several times a day. The global market for blood glucose monitoring systems was $ 9bn in the year 2010 with a CAGR of 6.6% since 2005. —— Besides the diabetes market, DirectSens targets emerging business segments for biosensors such as the fast-growing 2nd generation bioethanol market or the dairy industry with a focus on lactose-free products.
118
Products
Application
Stage of development
—— Blood glucose test strips
Blood glucose monitoring
GMDN 30221 class IIa, under developement
—— Continuous blood glucose monitoring system
Blood glucose monitoring
GMDN 34220 class III, under developement
—— Lactose/cellulose test strips
Process control
Under developement
Company Profile Founded: 2013 Legal Form: GmbH Employees: 4
DirectSens biosensor technology
Management Team CEO: Christoph Sygmund, Roman Kittl CFO: Gerald Schaufler Cofounders: Christoph Sygmund, Roman Kittl, Alfons Felice, Wolfgang Harreither, Roland Ludwig Public Funding aws PreSeed: € 140,000 Others(accent): € 60,000 Private Funding
DirectSens GmbH Am Rosenbühel 38 3400 Klosterneuburg, Lower Austria, Austria +43 699 18355188 office@directsens.com www.directsens.com
€ 68,000
Medtech – 119
EMCOOLS Medical Cooling Systems is a rapidly growing Austrian medical device company with the mission to improve the quality of patient care during therapeutic cooling. The unique and patented HypoCarbon® Technology Pads provide outstanding cooling rates for fast and efficient patient cooling and are able to cover the whole cooling chain from the pre-hospital ambulance service / air rescue through to the in-hospital setting. Indications for cooling therapies are cardiac arrest, myocardial infarction, stroke, sepsis and various hyperthermic diseases.
Products Products
Application
Stage of development
TH/TR
Class IIa E (=Europe), approved
—— Flex.PadTM Small
TH/TR
Class IIa E, approved
—— Brain.Pad
TH/TR
Class IIa E, approved
—— Brain.PadTM Small
TH/TR
Class IIa E, approved
—— Air.Pack
TSS
Class I E, approved
—— Six.Pack
TSS
Class I E, approved
—— Six.Pack XL
TSS
Class I E, approved
—— Box
TSS
Class I E, approved
—— Flex.Pad
TM
TM
TH/TR: Therapeutic Hypothermia / Temperature Reduction TSS: Transportation and storage system
Technology
Market
—— HypoCarbon®, the patented EMCOOLS technology for easy and efficient cooling, ensures that the surface cooling systems EMCOOLS Brain.PadTM and Flex.PadTM provide highly efficient cooling rates of up to 3.3 °C per hour. —— The thermal conductivity (“cooling velocity”) of HypoCarbon® is 15 x higher than that of ice and 58 x higher than that of water.
—— Product clearance in Europe, US, Brazil, China, and Japan. By summer 2012, more than 100,000 pads had been used worldwide to the benefit of more than 10,000 patients. —— Distribution partners in more than 40 countries worldwide.
120
Emcools Medical cooling pads Company Profile Founded: 2005 Legal Form: AG Employees: 20 Management Team CEO: Michael Kühling Public Funding aws Seed: € 500,000 aws Double Equity: € 1.19M Others (FFG): € 44,000
EMCOOLS Medical Cooling Systems AG Bruckner Straße 6/7a 1040 Vienna, Austria +43 225 289 015 20 emcools-office@emcools.com www.emcools.com
Medtech – 121
EMTensor
Products
is a medical device company that researches and commercializes electromagnetic (microwave) imaging technology and products for biomedical use using safe levels of electromagnetic fields from the non-ionizing spectrum. The company researches and develops novel 4D electromagnetic imaging technology and devices, unifying anatomical and functional capabilities in a single technology. The mobility of the technology will enable its use in different areas (ambulance, rescue helicopter, rural area, etc.). The company addresses the growing demand for cost-effective, safe, and mobile imaging technologies needed for a wide range of medical applications such as stroke, brain injuries, and various types of cancer and body injuries. The most advanced project of generation 1 is currently undergoing clinical trials with stroke patients.
Products
Application
Stage of development
—— BrimG1
Stroke
Class IIa
Market —— EMTensor GmbH addresses a market of approximately 15 million people suffering stroke worldwide every year. Of these, 5 million die and another 5 million are permanently disabled. Stroke in Europe accounts for 1.1 million deaths per year. Stroke together with cardiac infarct is also the leading cause of death in Austria. By reducing the time to treatment, the average 5-10% (depending on the country) DALY´s lost by stroke could
be reduced. Stroke is a leading cause of disability affecting physical, cognitive, communicative, and social domains. Stroke is responsible for a burden of about 2.2% of total health costs. —— Medical imaging equipment market revenue is estimated to grow at a CAGR of 4.4 % from 2012 to 2017. —— EMTensor GmbH’s first target market will be Europe and USA.
Technology —— The biological object is within EM fields and is created by a plurality of transmitters. Sensors measure complex EM fields affected by the presence of the biological object. Highly sophisticated algorithms are used to inverse a “data tensor” and reconstruct a 3D distribution of dielectric properties within biological objects to obtain an image of the object. Technically, EMT technology works in a similar fashion as traditional tomographic imaging modality. However, instead of a measurement of characteristics based on X-ray radiation (as 122
in CT), EMT sensors measure complex scattered EM field (amplitude and phase). The level of EM field used in imaging procedures is less than the level of EM field used in cell phones. This is a technique that is non-invasive, mobile, easily applied, and can monitor the patient continuously in real-time, either at the bedside or in the emergency department. —— More than € 155,000 has been invested for protecting the intellectual property only. EMTensor has five issued patents and nine patents pending.
Company Profile Founded: 2012 Legal Form: GmbH Employees: 6 Management Team CEO and founder: Serguei Semenov Public Funding
EMTensor GmbH Donau-City-Strasse 1 1220 Vienna, Austria +43 1 890 661 2 office@emtensor.com www.emtensor.com
aws Seed: € 750,000
Medtech – 123
Ergospect
Products
specializes in the development and production of diagnostic pedals for the examination of different muscle groups, the myocardium, and the musculoskeletal system, to simulate stress situations or physical exercise inside the MRI bore.
Technology
Market
—— The diagnostic pedals produce physical stress within the MRI bore. Examinations are simultaneously monitored and evaluated by highly sophisticated analytical software. Based on the implementation of various MR technologies, numerous biological parameters can be measured under physiological and pathological conditions. —— The devices are pneumatic and work with optosensors. They are easy to use in a daily clinical routine and compatible with any MRI up to 9 Tesla and higher. —— Ergospect holds patents in Germany, UK, France, USA, India, and China.
—— In 2008, the global market for MRI ergometry accounted for over $ 3bn. The estimated annual growth rate is approx. 10%. —— Developed countries show growing sensibility toward diagnoses in the field of vascular surgery, orthopedics, angiology, cardiology, and sports medicine. Effective methods like the Ergospect devices for dynamic MRI stress testing will be in demand in order to detect certain indications accurately. —— Ergospect’s primary target markets are Europe, North America, and Asia. The company benefits from close scientific cooperation with different leading international university institutes.
124
Products
Application
Stage of development
—— Trispect® Module
Calf muscle
Class I, approved
—— Quadspect® Module
Quadriceps muscle
Class I, approved
—— Glutspect Module
Gluteus muscle
Class I, approved
—— Cardiologic Module
Cardiovascular system
Class I, approved
—— Orthospect® Module
Musculoskeletal system (joints and spine)
Class I, under development
Ergospect diagnostic pedals Company Profile Founded: 2008 Legal Form: GmbH Employees: 6 Management Team CEO: Thomas Hugl CSO: Michael Schocke Public Funding aws PreSeed: € 55,000 aws Seed: € 400,000 Others (CAST, Land Tirol K-Regio): € 645,000
Ergospect GmbH Oppolzerstraße 6 6020 Innsbruck, Tyrol, Austria +43 699 160 202 00 info@ergospect.com www.ergospect.com
Medtech – 125
impress
Products
strives for the implementation of a simple-to-use, reliable system for non-invasive continuous blood pressure measurement as a new clinical standard: Patients will be spared pain and the risk of complication while health care providers will be able to better monitor their patient’s status and thus improve patient outcomes and save costs.
Technology —— 20% of all surgeries, or more than 50 million, per year worldwide – from Cesarean section to hip replacements – require continuous blood pressure monitoring. Until today, no non-invasive method exists that is suitable for clinical practice, thus making monitoring this vital sign unnecessarily painful, risky, time–consuming, and expensive. —— impress provides continuous non-invasive blood pressure measurement utilizing a cheap, robust, and clinically well-known setup. impress ties easily into existing multi-parameter monitoring equipment and requires practically no instrumentation training, thus allowing for fast acceptance as the clinical standard. —— impress technology is patented in Europe (PCT/EP2010/062873), with applications in US and Japan. 126
Products
Application
Stage of development
—— Impress BP Monitor
Non-invasive continuous clinical blood pressure monitoring
Class IIb, under development
Market —— The global market for non-invasive, continuous blood pressure measurement devices in 2013 is estimated at € 1.3bn. —— Disposable electrodes represent substantial potential. —— impress builds its GTM strategy around clinical application areas with high potential and considerable size, geographically in Europe and markets with high demand, to enhance health care and to face challenges where non-invasive methods are preferable and where reasonable market entrance hurdles exist.
Company Profile
impress Team: Arnulf Heller (center left), Christopher Arbeiter (center right), Eva Grieshuber, Bernd Höfler
Founded: 2013 Legal Form: e.U. Employees: 1 Management Team CEO: Arnulf Heller Christopher Arbeiter Eva Grieshuber Bernd Höfler Martin Götting (fundraising) Public Funding aws PreSeed: € 200,000 FFG Basis: € 170,000
Impress MedTech e.U. Plüddemanngasse 39 8010 Graz, Styria, Austria +43 664 5411121 arnulf.heller@smartnibp.com
Medtech – 127
iSYS Medizintechnik is an independent and highly specialized medical device manufacturer, focused on developing innovative (robotic) solutions for micro invasive interventions. iSYS offers a competitive superiority through unique technology, combined with accessories for active and passive image-guided navigation. In this novel approach, a small, modular robotic system is integrated into existing and future technologies. This will allow image-guided interventions to become not only more precise but also more efficient and less invasive, leading to improved user and patient safety and therapeutic outcomes.
Technology
Market
—— The iSYS 1 Interventional Platform is a modular needle guidance platform for interventional radiology and related fields. —— Core components are a 4 DOF Robotic Positioning Unit, which allows submillimetric needle positioning as well as angulation and a control unit that is controlled by a cable-connected Handheld Control Unit. —— The passive macro positioning unit and different table adapters allow different setups of the system around the patient in the region of interest while still providing maximum rigidity. —— The needle-guide-set provides disposables that ensure precise & sterile needle guidance. —— Planning of the intervention is based on digital image data acquired intra-operatively using different kinds of modalities, like CT or 3D-fluoroscopy.
—— According to experts, the robotic market has great potential in several medical fields. —— Computer- and robot-supported systems are among the standard equipment of university hospitals today. Robotic systems are already being deployed in various medical fields such as orthopedics, radiology, and oncology. —— There is a special potential for robotics in oncology because of increasing cancer incidences and inefficient treatment methods. —— 24.6 million people suffer from cancer at the moment; the estimated number of new cancer incidences per year is expected to rise from 10.9 million in 2002 to 16 million by 2020. —— There are various cancer treatment methods that can be significantly improved through the use of medical robots.
128
Products Products
Application
Stage of development
—— iSYS 1 CB-CT
Interv. Radiology, Oncology, Computer-Assisted Surgery
Class I, approved
—— iSYS 1 ICT
Interv. Radiology, Oncology, Computer-Assisted Surgery
Class I, approved
—— iSYS 1 CT Navi+
Interv. Radiology, Oncology, Computer-Assisted Surgery
Class I, approval procedure
—— iFix
Interv. Radiology, Oncology, Computer-Assisted Surgery
Class I, approval procedure
—— MTD
Interv. Radiology, Oncology, Computer-Assisted Surgery
Class I, approval procedure
—— SBP
Interv. Radiology, Oncology, Computer-Assisted Surgery
Class I, approved
Company Profile Founded: 2010 Legal Form: GmbH Employees: 8
iSys robotic solutions for micro invasive interventions
Management Team CEO: Michael Vogele CFO: Thomas Pfeifer Public Funding aws (PreSeed, Seed, Double Equity): € 1.75M Others (CAST): € 50,000 Private Funding
iSYS Medizintechnik GmbH Bergwerksweg 21 6370 Kitzbühel, Tyrol, Austria +43 664 241 114 0 info@isys.co.at www.isys.co.at
€ < 1.5M
Medtech – 129
Jeder
Products
Easier dental implants by secure, minimally invasive sinus augmentation. The Jeder-System offers easy and secure sinus augmentation by using high hydraulic pressure and providing real-time feedback to the surgeon. One in four dental implants require prior bone grafting, with sinus augmentation being one of the most frequently performed grafting procedures. Bone mass is increased in the upper jaws of a patient by placing bone replacement material between the sinus membrane and the jaw bone.
Technology
Market
—— For dentists and oral/maxillofacial surgeons, the Jeder-System improves outcomes for sinus augmentation and provides a simpler, easier-to-use system for the surgeon. —— Novel method of using high (1.5 bar) hydraulic pressure in a controlled way for a minimally invasive sinus augmentation —— Protected by 4 patent families in more than 30 countries
—— In 2010, more than 1 million dental implants were placed in Germany. Of those, 25% needed some form of bone grafting. —— Globally, there are more than 100,000 implantologists placing some 6 million dental implants annually.
130
Products
Application
Stage of development
—— Jeder-System
Minimally in-vasive bone grafting for placing dental implants
Class IIa, approved
Company Profile Founded: 2010 Legal Form: GmbH Employees: 4
The Jeder technology
Management Team CEO: Andreas Bayerle CSO: Michaela Bayerle-Eder CTO: Klaus Eder CMO: Philip Jesch Public Funding aws Seed: € 600,000 Others (NÖBEG): € 400,000 Private Funding
Jeder GmbH Starkfriedgasse 62 1190 Vienna, Austria +43 1 4700 165 office@jedersystem.com www.jedersystem.com
Not disclosed
Medtech – 131
Lacerta Technologies is a regenerative medicine company that aims to translate research results into products for routine clinical use. We place special emphasis on designing simple and affordable protocols to allow a wider patient population to benefit from cell therapy.
Technology
Market
—— Serum-albumin-coated bone grafts. An off-the-shelf bone substitute, which has most of the benefits of stem cells and growth factors without their cost and complexity. It induces the patient’s own stem cells to proliferate, resulting in fast remodeling of the graft. —— GraftBuilder Stage 1. A point-of-care device for isolating a proprietary growth factor mix (serum from platelet-rich fibrin) from the patient’s blood. Ready to be reapplied in 15 minutes in orthopedics and sports surgery indications. —— GraftBuilder Stage 2. A custom-made bone graft system for specialized clinics and tissue banks. It is capable of creating personalized bone graft coatings for demanding cases where inducing bone formation and fighting bacterial infection are both necessary. —— IP: 1 granted and 4 pending patents
—— Bone is the second-most-frequently transplanted human tissue. Due to the limited availability and complications in harvesting autografts, a variety of bone graft substitutes (allografts, growth factors, cell-, ceramic-, or polymer-based grafts) has been developed. Today, they represent a global industry of $ 2.5bn annually, with the US being by far the largest market with more than 1 million grafting procedures performed annually. The two professions that use the majority of bone grafts are orthopedic and dental surgeons, facing the problem of a lack of suitably strong bone to support a metal implant. Lacerta’s market niche is improved bone grafts that support the patient’s own stem cells to regenerate the tissue and fight bacterial infection to preserve the graft.
132
Products Products
Application
Stage of development
—— Albumin bone graft
Dental, orthopedic, off-the-shelf
Tissue product, first-in-human
—— Antibiotic bone graft
Dental, orthopedic, off-the-shelf
Drug-device combination, preclinical
—— GraftBuilder Stage 1
Sports and orthopedic surgery, point-of-care
Class IIa, lab prototype
—— GraftBuilder Stage 2
Orthopedics, personalized graft
Class IIa, preclinical
—— Imaging Chamber
Live cell microscopy
Lab device, prototype
Company Profile Founded: 2012 Legal Form: GmbH Employees: 4
Lacerta Team and Technology
Management Team CEO: Zsombor Lacza CFO: Björn Ehring Public Funding aws Seed: € 750,000 Others (ACCENT): € 50,000 Private Funding
Lacerta Technologies GmbH Dr. Karl-Dorrek Str. 23-29 3500 Krems an der Donau, Lower Austria, Austria +43 664 883 162 05 zsombor.lacza@lacertatech.com www.lacertatechnologies.com
€ 75,000
Medtech – 133
medizinkraft solutions develops an integrated system (hardware and software) for applications in the treatment of musculoskeletal disorders using remote sensing technologies (temperature, depth, RGB). By aggregating the sensor data, a precise 3D representation of the body is generated in real-time, allowing an accurate determination of the skeleton and motion tracking, which is used in diagnostic as well as in therapeutic contexts.
Technology
Market
—— “MotionAid,” the product developed by medizinkraft solutions, is an embedded system that integrates several sensors and a high-performance single-board computer in a single box. It requires no other local infrastructure than a TV set with an HDMI interface. It is operated and controlled remotely by gestures. —— MotionAid is a class Im medical device compliant with IEC 62304, ISO 13485, and ISO 14971.
—— In the first step, MotionAid will be launched in the German-speaking countries (D-A-CH region) for supporting diagnosis and rehabilitation after total knee (TKR) and total hip replacement (THR). —— In 2010, a total of 191,845 TKR and 249,281 THR operations were performed in the D-A-CH region; the number is steadily increasing.
134
Products Products
Application
Stage of development
—— MotionAid
Musculoskeletal disorders
Class Im, under development
medizinkraft Management Team: Michael Matzner, Christian Kocourek and Peter Marksteiner
Company Profile Founded: 2012 Legal Form: GmbH & CO KG Employees: 11 Management Team CEO: Christian Kocourek CMO: Michael Matzner CTO: Peter Marksteiner Public Funding
medizinkraft solutions GmbH & CO KG Dr. Franz-Wilhelm-Straße 2 3500 Krems an der Donau, Lower Austria, Austria +43 1 403 991 8 office@medizinkraft.com www.medizinkraft.com
aws PreSeed: € 200,000
Medtech – 135
Murmur Detect
Products
provides medical professionals with clinically proven tools for the detection of pathological heart conditions with an emphasis on automated, non-invasive products that yield fast, reliable, diagnosis-assisting results right at the patient’s side.
Products
Application
Stage of development
—— Heart murmur detection assistant
Automated auscultation assistant
IIa, under development
Technology —— Background: Newborns demand special medical attention and protection. One routine examination is the auscultation of the heart with a stethoscope, a well-established and standardized method performed by doctors worldwide wherein they distinguish between “normal” and pathological heart sounds. Fast heartbeats, the unsettled and agitated behavior of the babies, and a frequently noisy hospital environment make a successful diagnosis particularly challenging. If diagnosed too late, or in a worst-case scenario diagnosed incorrectly, a whole spectrum of serious consequences can arise. —— Technology: Murmur Detect developed algorithms capable of analyzing heart sounds fully automated. Based on superior, patent-pending technologies, Murmur Detect provides tools for medical professionals to assist them in detecting and diagnosing clinically relevant heart conditions, based on well-defined scientific criteria. The algorithms are fast and can be utilized right at the patient’s side, without interfering with the clinical routine. The results are fewer false diagnoses and the earlier detection of heart murmurs, leading to more efficiency and effectiveness in the medical treatment of newborns; time saved for the medical 136
staff; a reduction in unnecessary follow-up examinations; and, in turn, to long-term cost reductions for the medical system.
Market —— Market Segments: Based on different medical needs between patient groups, Murmur Detect develops specialized tools tailored to patient requirements: Infant system: for premature babies and newborns; Pediatric system: for children; Adult system: for adults, aged 50+ —— Market Volumes: Murmur Detect algorithms can be utilized in combination with electronic stethoscopes. The global stethoscope market volume in 2017 is estimated to be € 263M. —— Currently, Europe and the USA comprise the biggest markets, while Asia shows the highest growth rate with +4.5% per year, especially in the electronic stethoscope segment at the expense of mechanical stethoscopes. —— Potential end users of Murmur Detect tools include: nurses, nurse practitioners, physician’s assistants, midwives, neonatologists, cardiologists, pediatricians, family doctors, medical responders, Red Cross employees, NGOs, general practitioners, etc.
Murmur Detect technology
Company Profile Founded: Planned for 2014 Legal Form: GesmbH light Management Team CEO, co-founder: Andreas Schriefl CSO, co-founder: Andreas Reinisch Public Funding aws PreSeed: € 200,000 Private Funding
Murmur Detect Plüddemanngasse 39 8010 Graz, Styria, Austria +43 660 6555 880 info@murmurdetect.com www.murmurdetect.com
€ 26,000
Medtech – 137
mySugr
Services
is an m-health service company that focuses on making the life of diabetics easier and more fun. We specifically target the motivation component of diabetes treatment.
Services
Description of Service
—— mySugr Companion
The logbook is a powerful and important tool to help people with diabetes (PWD) to self-manage their disease. The Companion is a charming, sometimes outspoken diabetes manager. The app has a similar purpose to a diabetes logbook. It provides immediate feedback and helps people with diabetes to stay motivated.
—— mySugr Junior
Managing day-to-day life with diabetes is a challenging task, especially for the little ones. mySugr Junior is a smart logbooking app that helps children, who still need their parents’ support, to master this great challenge day by day. mySugr Junior not only makes it possible for our little ones to be more independent in their carefree day-to-day life, but it also teaches them in a playful way how to deal with their diabetes.
Technology / Innovation
Market
—— Smart logbook: Clever, fast, and valuable logging. The smart phone enriches manually entered data with automatically generated information. —— Gamification: We will create a positive feedback culture through game challenges. We reward action and ultimately visualize therapy progress. —— Caring and sharing: We will be matching up diabetics with corresponding therapy patterns to stimulate positive behavior. —— Compliance: The application aids compliance through the use of motivational triggers. It gives feedback on the current therapy state and rewards diabetics striving for therapy compliance. This leads to the user being aware of the positive effects of therapy and supports awareness.
—— 350M diabetics worldwide —— € 137bn spent annually by European health care on patient treatment —— 20% increase in Europe by 2030 —— 73% of diabetics do not log their data
138
The mySugr Service Company Profile Founded: 2010 Legal Form: GmbH Employees: 8 Management Team CEO: Frank Westermann CSO: Gerald Stangl Public Funding aws Seed: € 750,000 aws PreSeed: € 149,000 Others (Impulse XL): Not disclosed
mySugr GmbH Siebenbrunnengasse 44 1050 Vienna, Austria +43 699 11109779 support@mysugr.com www.mysugr.com
Biotech / Pharma – 139
ScarletRed
Products
focuses on emerging technologies in the field of biomedical engineering to develop innovative products for state-ofthe-art medical diagnostics and therapy. After successful proof of concept of its lead medical device candidate (SCR001), substantial PreSeed funding could be gained to secure CE marking. The novel technology enables objective remote visual assessment of drug and treatment efficacy by providing a real-time data link between trial sponsor and local physicians. This positively impacts the process of clinical testing by reducing time, risk, and opportunity costs. Technology leadership and first-mover advantage provide a significant competitive edge for the startup to enter the global market.
Technology
Market
—— Prototype developed during phase 1b safety and efficacy testing of an IND in irradiated cancer patients —— Remote and standardized single/multicentric clinical observations of epithelial areas without physical contact with inflamed, damaged, or infectious areas —— GCP-compliant anonymization and blinding of medical data according to international IHC standards —— Device works wireless and independent of location —— Compatible with smart phones and tablet computers
—— Global clinical drug testing market —— Remote patient monitoring: € 27M (2013) – € 50M (2017), CAGR 16.5% —— Acute and chronic wound care market: € 16bn (2011) – € 23bn (2016); CAGR 7.3% —— Cancer irradiation incidence rate 2012: Breast/HNC irradiation: 2.3M —— Dermatologic drug testing: Acne (cosmetics, cancer therapy): 82M, Atopic dermatitis: 240M
140
Products
Stage of development
—— SCR001
eMedical device (class IIa); clinical testing for CE mark
—— License
By fee for use according to EULA
—— Patent
Filed 2013 by international prio-application
Services —— App for objective analysis of erythema and wound healing —— Electronic medical data processing center —— Clinical trial design and consulting —— Biostatistics report
ScarletRed technology Company Profile Founded: 2013 Legal Form: GmbH i.G. Employees: 4 Management Team CEO: Harald Schnidar Public Funding aws PreSeed: Not disclosed Others (FFG Innovation-Scheck): Not disclosed Private Funding
ScarletRed Biomedicals GmbH i.G Würffelgasse 4 T66 1150 Vienna, Austria +43 664 885 062 46 ofice@scarletred.at www.scarletred.at
Not disclosed
Medtech – 141
SIMCharacters
Products
develops pediatric patient simulators. The convincingly life-like simulators enable a previously unattainable degree of effectiveness to be achieved during simulation-based training sessions in medicine. The medical care of a critically ill child is a rare event, even for the majority of pediatricians. If the right steps are not taken during treatment, this can have a life-long impact on the further development of the child. The SIMCharacters patient simulators combine modern technology, making it possible to simulate pathologies and extremely realistic internal and external anatomy for the first time. This helps health care professionals to save children´s lives.
Technology —— SIMCharacters combines a high degree of technical expertise in the realistic implementation of previously unsimulatable pathologies by means of miniaturization and the development of completely novel simulation components (e.g. breathing-related pathologies). This results in high-fidelity pediatric patient simulators. —— SIMCharacters holds patents on several simulator-related components. 142
Market —— Customers: Simulation centers (public and privately owned), Universities, Teaching hospitals. —— Market potential focused market segment: € 95M p.a. —— Market growth focused market: 15% – 20% p.a. (Europe, US, Asia) —— SIMCharacters targets the worldwide market of simulation technology
Products
Stage of development
—— SIMCharactersPreterm
Under development
Company Profile Founded: 2012 Legal Form: GmbH Employees: 1
SIMCharacters pediatric patient simulators
Management Team -
CEO: Jens-Christian Schwindt Finance: Michael Hoffmann R&D: Ewald Unger Art Director: Christoph Kunzmann
Public Funding aws PreSeed: € 220,000 Others (PRIZE): € 150,000 Private Funding
SIMCharacters GmbH Geblergasse 66/10 1170 Vienna, Austria +43 699 196 898 78 Jens.schwindt@simcharacters.com www.simcharacters.com
€ 20,000
Medtech – 143
TissueGnostics
Products
is an innovative R&D company that develops and sells bestin-class systems for use in scientific research and routine diagnostics. The company was founded in 2003 based on preceding academic development at the Medical University of Vienna and has subsidiaries in Romania and the USA. With 140+ unique installation sites and 270+ total software licenses in Europe, North America, Asia, and the Middle East and 100+ scientific publications, the company is well perceived within the international scientific community.
Products
Description
—— TissueFAXS
Cancer research, Immunology, FISH, TMA, Cell culture analysis
—— HistoFAXS
Immunohistochemistry, Histology, Basic scientists, TMA
—— PathoFAXS
Routine pathologists, including fully automated and clinically tested analysis profiles and reports
—— HemoFAXS
Hematology and laboratory medicine
—— StrataFAXS
A new generation of interactive high-speed scanning and analysis platform
Technology —— High-speed scanning technology for brightfield and fluorescence slides as well as culture plates —— Automated workflow from single slide systems up to 200 slides or 20 culture plates, high-throughput imaging platforms —— IVD conform image analysis suitable for pathology and hematology as well as cancer and clinical research —— HistoQuest for histopathology has been used extensively in the fields of cancer research and immunology. —— TissueQuest is a suite for the simultaneous phenotypic and functional characterization of cells with several markers as well as FISH analyses. —— StrataQuest is a new multilayer image processing platform for automating 144
the complex multistep analysis that is needed in routine pathology and basic research. —— HemoQuest is a new multifunctional SW for automatic classification of leukocyte subsets in blood and bone marrow smears and body fluids.
Market
Company Profile
Tumor cells (in red) within a distance of 10 µm of the next blood vessel (close tumor cells in green, and blood vessels in gray)
Founded / 2003 Legal Form / GmbH Employees / 31 Management Team
—— TissueGnostics innovative products address 4 different market segments. Segment / 2011 / CAGR 2011-2016 —— IVD / $ 44bn / +7.8% —— Cell & Tissue analysis / $ 6.9bn / +9.6% —— Digital Pathology / $1.9bn / +12% —— Hematology / $ 5.7bn / +5%
CEO/CSO / Georg Steiner CEO/CFO / Rupert Ecker Public Funding (aws Seed, aws Double Equity, EU Grants, ZIT, FFG, WWTF): € 4.3M Private Funding
TissueGnostics GmbH Taborstrasse 10/2/8 1020 Vienna, Austria +43 1 2161190 90 office@TissueGnostics.com tissuegnostics.com
€ 2.833M
Medtech – 145
Tyromotion
Products
is one of the worldwide leading providers of robotics and computer-aided therapeutic devices in the area of neuro and orthopedic rehabilitation. The product portfolio includes tailor-made solutions for the upper extremities, especially for hand, arm, and finger rehabilitation. The company‘s focus is on the development of new technologies of high-performance mechatronic systems in rehabilitation. The sales network extends to 30 partners across the globe. Tyromotion cooperates in the development of therapy devices with renowned research partners such as the Columbia University in New York or the Johns Hopkins University in Baltimore.
Products
Application
Stage of development
—— Amadeo®
Finger, hand rehabilitation
Approved
—— Pablo®
Hand, arm rehabilitation
Approved
—— Tymo®
Hand, arm rehabilitation
Approved
—— Diego®
Arm rehabilitation
Approval procedure
—— tyrostation
Workstation for Tymo & Pablo
Approved
Tyromotion product Company Profile Founded: 2007 Legal Form: GmbH Employees: 26
Technology
Market
—— Robot- and computer-aided therapy devices for upper-extremity rehabilitation.
—— Primarily Tyromotion targets the Western European, Asian, and American markets with 1.2 million stroke patients a year, of which about 25% are eligible for hand exercising therapy
146
Management Team CEO: Ram David CEO: Alexander Kollreider Public Funding aws PreSeed: € 77,000 others: not disclosed Private Funding not disclosed
Tyromotion GmbH Bahnhofgürtel 59 8020 Graz, Styria, Austria +43 316 908 909 info@tyromotion.com www.tyromotion.com
Medtech – 147
VASCOPS
Products
develops new A4clinics software screens for patients at high risk of life-threatening vascular rupture. The ballooning of a blood vessel is referred to as an aneurysm. If this occurs in the aorta and this subsequently ruptures, the consequences are immediately fatal. The novel A4clinics software from VASCOPS supports physicians who have to make patient-specific risk assessments by allowing rapid screening and detection of patients at highest risk of rupture.
Technology
Market
—— Localized ballooning of the abdominal aorta is a predominant risk factor for aortic rupture, which may lead to death within minutes. —— VASCOPS develops software programs based on CT data that generate images within a few minutes, showing pressure of the vascular wall. —— This patient-tailored imaging technology allows quick and qualitative AAA rupture risk assessment, thereby providing data that support the decision making for surgical interventions. —— Legal protection is given in terms of holding international patents to protect all novel algorithmic steps.
—— Despite the implementation of different health care programs, cardiovascular diseases are still the main cause of death in the Western world. —— 6% of the European population is affected by AAA, necessitating approximately 50,000 examinations a year. —— Numbers are increasing due to AAA screening programs and an aging population. —— There is no comparable AAA rupture risk assessment method on the market assuming high market volume potential.
148
Products
Application
Stage of development
—— A4clinics
Medical software
Class IIb, approved
—— A4clinics Research Edition
Medical research software
Class IIb, approved
—— TAA (Thoracic Aneurysm Analyzer)
Software to define the rupture risk of thoracic aortic aneurysms
Class IIb, preclinical
—— CPVA (Carotid Plaque Vulnerability Analyzer)
Software to define the rupture risk of carotid plaques
Class IIb, under development
—— GP (Growth Predictor)
Software to compute the growth of AAA by a diagnostic prognosis
Class IIb, under development
Vascops technology
Company Profile Founded: 2009 Legal Form: GmbH Employees: 4 Management Team CEO: Carmen Gasser CTO: Thomas Christian Gasser CSO: Martin Auer Public Funding aws PreSeed: € 100,000 aws Seed: € 500,000 others (Science Park Graz): € 52,200
VASCOPS GmbH Plüddemanngasse 39 8010 Graz, Styria, Austria +43 660 765 513 1 office_at@vascops.com www.vascops.com
Medtech – 149
VASEMA
Products
is an ISO 13485 manufacturer of high-tech medical devices designed for skin diagnostics. The first class IIa product – dermaMeter® professional 100 – represents a real milestone in this area. The company’s objective is to provide solutions for the global challenges concerning skin health.
Technology
Market
—— For the first time in the history of skin diagnosis, everyone can measure their skin health through the TEWLvalue (transepidermal water loss) objectively and reliably within a few seconds. —— The dermaMeter® is wireless, easy to use and always ready for use; hygiene caps meet the highest hygiene standards and guarantee a safe and sterile measurement. —— VASEMA holds patents on technology and applications, the trademarks, and the designs.
—— Due to increasing life expectancy, chemical, physical, and psychological stress factors, and people’s growing health consciousness, skin diseases are on the rise and prevention of diseases is getting more and more important. —— The market for our products has been evaluated by a number of active physicians in seven selected European countries. In these countries alone, there is a potential of € 1.5bn with an annual growth rate of 19%. —— VASEMA’s first target market will be Europe and the Middle East.
150
Products
Application
Stage of development
—— dermaMeter®
Skin diagnosis and monitoring
Class IIa, approved
—— dermaMeter® – Hygiene cup
Sterile measurement
Class IIa, approved
—— Apps
Data handling
Class I, under development
—— dermaMeter®
Rheumatism
Class IIa, under development
Company Profile
Vasema product dermaMeter®
Founded: 2010 Legal Form: GmbH Employees: 3 Management Team CEO, founder: Peter Hagl Public Funding aws PreSeed: € 170,000 aws Seed: € 750,000 departure focus design: € 162,191 INiTS: € 27,900 Private Funding
VASEMA GmbH Brunner Straße 67 / 4 1230 Vienna, Austria +43 1 890 4833-200 office@vasema.com www.vasema.com
€ 659,290
Medtech – 151
50.000 Euro
aws Temporary 3 × 1,500 Euro Management Financing of complementary
Business Idea expertise management www.awsg.at/maz
Phase 1 2.6. – 27.11.2014
g bu et y st sin ou ar es r te s d!
10,000 Euro LISAvienna Medtech Award
1.000.000 Euro aws Seedfinancing Financing the start-up phase of life science companies www.seedfinancing.at
1. 15,000 Euro 2. 10,000 Euro 3. 5,000 Euro
Advancing Austrian life science at the heart of Europe
Business Plan
200.000 Euro
Phase 2 aws PreSeed Financing the 28.11.2014 – 6.5.2015 pre-start phase www.preseed.at
aws best of biotech
International Biotech & Medtech We bring Life Sciences Business Plan Competition
to Life
www.bestofbiotech.at
www.lifescienceaustria.at
www.LifeScienceAustria.at
3 × 1,500 Euro Business Idea Phase 1 2.6. – 27.11.2014
g bu et y st sin ou ar es r te s d!
10,000 Euro LISAvienna Medtech Award
1. 15,000 Euro 2. 10,000 Euro 3. 5,000 Euro Business Plan Phase 2 28.11.2014 – 6.5.2015
aws best of biotech International Biotech & Medtech Business Plan Competition www.bestofbiotech.at
Austria Wirtschaftsservice Gesellschaft mbH WalcherstraĂ&#x;e 11A 1020 Vienna T +43 1 501 75-100 E 24h-auskunft@awsg.at www.awsg.at